Human Telomerase Reverse Transcriptase (TERT): Structure, Function, and Regulation

Introduction

Telomerase reverse transcriptase (TERT) is the catalytic protein subunit of the telomerase ribonucleoprotein enzyme complex, responsible for maintaining telomere length at the ends of linear chromosomes. In humans, TERT (UniProt: O14746; NCBI Gene ID: 7015) is encoded by the TERT gene located on chromosome 5p15.33 and consists of 1132 amino acids with a molecular weight of approximately 127 kDa [meyerson-1997-hTERT-cloning-abstract]. The enzyme catalyzes the addition of TTAGGG repeats to chromosome 3' ends using an internal RNA template provided by the telomerase RNA component (TERC/hTR), thereby counteracting the end-replication problem and enabling unlimited cellular proliferation [podlevsky-2012-telomerase-review-abstract].

The discovery of telomerase traces back to the seminal work of Carol Greider and Elizabeth Blackburn in 1985, who first identified telomerase activity in Tetrahymena extracts [greider-1985-telomerase-discovery-abstract]. This foundational discovery, along with Jack Szostak's work on telomere function, was recognized with the 2009 Nobel Prize in Physiology or Medicine. The human TERT gene was subsequently cloned in 1997 by Meyerson, Weinberg, and colleagues, who demonstrated that TERT expression correlates with telomerase activity and is the rate-limiting component for telomerase function in human cells [meyerson-1997-hTERT-cloning-abstract].

TERT is particularly significant in cancer biology, as telomerase reactivation occurs in approximately 90% of human cancers, enabling tumor cells to bypass replicative senescence and achieve immortalization [dratwa-2020-TERT-regulation-cancer-abstract]. Understanding TERT's enzymatic mechanism, subcellular localization, and regulatory pathways is therefore essential for developing targeted cancer therapies and understanding cellular aging processes.

Protein Structure and Domain Organization

Human TERT contains four evolutionarily conserved structural domains that work together to accomplish the unique enzymatic function of telomere extension [podlevsky-2012-telomerase-review-abstract][wu-2017-telomerase-mechanism-abstract]. These domains are arranged linearly from the N-terminus to C-terminus: the telomerase essential N-terminal (TEN) domain, the telomerase RNA-binding domain (TRBD), the reverse transcriptase (RT) domain, and the C-terminal extension (CTE) domain.

The TEN domain, located at the N-terminus, is connected through a flexible linker to the remainder of the protein and serves critical roles in substrate handling and repeat addition processivity [wu-2017-telomerase-mechanism-abstract]. This domain traps single-stranded telomeric DNA and facilitates processive repeat synthesis by capturing the substrate and maintaining association with the single-stranded product during the catalytic cycle. The TEN domain also participates in the recruitment of telomerase to chromosome ends through its interaction with the shelterin component TPP1 [liu-2022-TPP1-telomerase-structure-abstract].

The TRBD is essential for telomerase RNA binding and activity both in vitro and in vivo [podlevsky-2012-telomerase-review-abstract]. This domain contains conserved T, CP, and QFP motifs that are critical for RNA interaction. The TRBD engages TERC through hydrogen bonds and electrostatic interactions, maintaining a stable yet flexible association that is necessary for template positioning and catalysis.

The RT domain contains the catalytic center of the enzyme and shares seven conserved motifs with conventional reverse transcriptases: motifs 1, 2, A, B', C, D, and E [podlevsky-2012-telomerase-review-abstract]. Motifs A and C contain a catalytic triad of universally conserved aspartate residues (D712, D868, and D869 in human TERT) that are essential for catalytic activity. These residues coordinate divalent metal ions (typically Mg²⁺) that stabilize the developing negative charge during nucleotide addition, a mechanism common to all polymerases [wu-2017-telomerase-mechanism-abstract]. A unique feature of the telomerase RT domain is the insertion in fingers domain (IFD), located between motifs A and B, which is thought to stabilize short RNA-DNA hybrids crucial for template translocation [podlevsky-2012-telomerase-review-abstract]. Recent cryo-EM studies have revealed an additional TERT-specific domain called TRAP (telomerase RAP motif) that participates in interactions with the shelterin protein TPP1 [liu-2022-TPP1-telomerase-structure-abstract].

The CTE domain contributes to structural stability and may enhance nucleic acid association [podlevsky-2012-telomerase-review-abstract]. Crystal structures of the Tribolium castaneum TERT revealed that the TRBD, RT, and CTE domains fold together to form a toroidal (ring-like) structure with a central cavity that accommodates the RNA-DNA hybrid during catalysis [gillis-2008-tribolium-TERT-structure-abstract][mitchell-2010-TERT-nucleic-acid-binding-abstract]. Although Tribolium TERT lacks the TEN and TRAP domains present in human TERT, this ring structure has proven useful for modeling the human enzyme architecture.

Enzymatic Mechanism and Catalytic Activity

TERT catalyzes the addition of telomeric DNA repeats (5'-TTAGGG-3' in humans) to chromosome 3' ends, classifying it as a template-dependent DNA polymerase with EC number 2.7.7.49 [podlevsky-2012-telomerase-review-abstract]. Unlike conventional polymerases, telomerase uses an intrinsic RNA template provided by the TERC component rather than an external template strand. This unique arrangement enables telomerase to synthesize multiple telomeric repeats through a distinctive two-phase catalytic cycle [wu-2017-telomerase-mechanism-abstract].

The first phase is the nucleotide addition phase, during which TERT synthesizes a single telomeric repeat by copying the template region of TERC onto the chromosome 3' end. Human TERC contains an 11-nucleotide template sequence (5'-CUAACCCUAAC-3') that directs the synthesis of the hexanucleotide repeat 5'-GGTTAG-3' [podlevsky-2012-telomerase-review-abstract]. Nucleotide addition proceeds through the standard polymerase mechanism, with the conserved aspartate residues in motifs A and C coordinating two divalent metal ions that catalyze the nucleophilic attack of the primer 3'-OH on the α-phosphate of the incoming dNTP [wu-2017-telomerase-mechanism-abstract].

The second phase is template translocation, which is unique to telomerase among polymerases. After completing synthesis of one repeat, the enzyme must reposition the template to enable synthesis of additional repeats without dissociating from the DNA substrate [wu-2017-telomerase-mechanism-abstract]. This requires separation of the newly formed RNA-DNA hybrid, translocation of the RNA template by one repeat length (six nucleotides), and re-annealing of the template to the 3' end of the newly synthesized DNA. The precise mechanism of template translocation remains incompletely understood, but involves conformational changes in both TERT and TERC that maintain substrate retention while allowing template repositioning.

The ability to synthesize multiple repeats without dissociation is termed repeat addition processivity (RAP), and is a hallmark feature that distinguishes telomerase from conventional polymerases [wu-2017-telomerase-mechanism-abstract]. RAP requires the TEN domain anchor site, which binds single-stranded DNA upstream of the RNA-DNA hybrid and maintains association with the substrate during template translocation. A DNA hairpin model has been proposed to explain how the primer 3'-end remains engaged with the active site while the template translocates, with the complementary DNA repeat forming a transient non-canonical base-paired hairpin that is subsequently realigned for processive synthesis [wu-2017-telomerase-mechanism-abstract].

The cryo-EM structure of human telomerase holoenzyme bound to telomeric DNA revealed that only four base pairs form between the DNA substrate and RNA template at any given time, providing structural insight into the short RNA-DNA hybrid that facilitates template translocation [nguyen-2021-telomerase-DNA-structure-abstract]. Nucleotide selectivity is determined by contacts between the RNA template and RT domain motifs 2 and B', which position the solvent-accessible RNA bases close to the enzyme active site [mitchell-2010-TERT-nucleic-acid-binding-abstract].

Telomerase Holoenzyme Assembly and Composition

Active human telomerase functions as a large ribonucleoprotein complex containing multiple protein subunits in addition to TERT and TERC [nguyen-2018-cryoEM-telomerase-abstract][nguyen-2021-telomerase-DNA-structure-abstract]. Cryo-EM structures have revealed that the human telomerase holoenzyme adopts a bilobed architecture consisting of a catalytic core lobe and an H/ACA ribonucleoprotein (RNP) lobe.

The catalytic core contains one TERT molecule and the essential template and pseudoknot domains of TERC [nguyen-2018-cryoEM-telomerase-abstract]. In this lobe, TERC encircles TERT, adopting a well-ordered tertiary structure with surprisingly limited direct protein-RNA interactions. The pseudoknot forms a rigid arc-like structure that may contribute to the co-folding of TERT and TERC rather than direct catalytic function.

The H/ACA RNP lobe comprises two sets of heterotetrameric H/ACA proteins (dyskerin, NOP10, NHP2, and GAR1) and one Cajal body protein, TCAB1 [nguyen-2018-cryoEM-telomerase-abstract]. These proteins bind to the 3' end of TERC, which contains conserved H/ACA motifs found in small nucleolar RNAs involved in ribosome biogenesis. The H/ACA proteins are essential for TERC stability and processing, while TCAB1 directs telomerase localization to Cajal bodies.

A surprising discovery from high-resolution cryo-EM structures was the identification of a histone H2A-H2B dimer as an integral component of the holoenzyme [nguyen-2021-telomerase-DNA-structure-abstract]. This histone dimer binds to the CR4/5 domain of TERC, suggesting a previously unappreciated role for histones in telomerase RNA folding and function beyond their canonical nucleosomal function.

The molecular chaperones HSP90 and p23 are required for correct assembly and stabilization of the active telomerase complex [wu-2017-telomerase-mechanism-abstract]. Assembly of the catalytic core involves the binding of TERT to two distinct regions of TERC: the template/pseudoknot domain and the CR4/5 domain. Both interactions are essential for reconstitution of catalytic activity.

Subcellular Localization and Trafficking

TERT and the telomerase complex exhibit dynamic subcellular localization that is regulated by the cell cycle and is crucial for enzyme function [tomlinson-2006-telomerase-trafficking-abstract][tomlinson-2008-hTERT-localization-abstract]. In human cells, TERT contains both nuclear localization signals and mitochondrial targeting sequences, enabling its distribution among the nucleus, cytoplasm, and mitochondria [dratwa-2020-TERT-regulation-cancer-abstract].

Within the nucleus, telomerase localization follows a cell cycle-dependent pattern that couples telomere synthesis specifically to S phase, when DNA replication occurs [tomlinson-2006-telomerase-trafficking-abstract]. During G1 and G2 phases, TERT and TERC occupy distinct subnuclear compartments: TERC resides primarily in Cajal bodies, while TERT is found in nucleoplasmic foci. Upon entry into S phase, both components are recruited to telomeres, with localization peaking at mid-S phase. In approximately 19% of mid-S phase cells, TERC was found at telomeres, typically at one to five telomeres per cell, declining in late S phase [tomlinson-2006-telomerase-trafficking-abstract].

Cajal bodies serve as critical sites for telomerase maturation, assembly, and storage [tomlinson-2006-telomerase-trafficking-abstract]. The localization of TERC to Cajal bodies and telomeres is specific to cancer cells expressing active telomerase and is not observed in primary cells lacking TERT expression. Importantly, TERT is required for TERC localization to both Cajal bodies and telomeres: RNAi-mediated depletion of TERT causes loss of TERC from these sites without affecting TERC levels, while introduction of TERT into normal cells induces TERC accumulation at Cajal bodies and telomeres [tomlinson-2008-hTERT-localization-abstract]. This indicates that telomerase assembly precedes transport to functional locations, with TERT serving as the critical determinant for intranuclear trafficking.

The TCAB1 protein (also known as WDR79) plays a key role in telomerase localization by directing the complex to Cajal bodies [wu-2017-telomerase-mechanism-abstract]. TCAB1 binds to the CAB-box motif in TERC and is required for proper localization of telomerase to both Cajal bodies and telomeres.

Telomerase is also found in mitochondria, where it appears to have functions distinct from telomere maintenance [dratwa-2020-TERT-regulation-cancer-abstract]. Mitochondrial localization of TERT is regulated by phosphorylation, particularly at tyrosine 707. Oxidative stress promotes Src kinase-mediated phosphorylation of Y707, which triggers nuclear export and translocation of TERT to mitochondria. Conversely, dephosphorylation by the phosphatase SHP2/PTPN11 promotes nuclear retention. Within mitochondria, TERT may contribute to mitochondrial DNA protection, reduce reactive oxygen species production, and regulate mitochondrial gene expression.

Telomere Recruitment via Shelterin Complex

Recruitment of telomerase to chromosome ends in human cells is mediated by the shelterin complex, a six-protein assembly that caps and protects telomeres [liu-2022-TPP1-telomerase-structure-abstract][nandakumar-2012-TEL-patch-abstract]. The shelterin complex consists of TRF1, TRF2, RAP1, TIN2, POT1, and TPP1, with TPP1 serving as the direct recruitment factor for telomerase.

TPP1 interacts directly with TERT through a specific surface region called the TEL patch (TPP1 glutamate and leucine-rich patch) located within the N-terminal OB-fold domain of TPP1 [nandakumar-2012-TEL-patch-abstract]. The TEL patch contains four glutamic acid residues that confer a negative charge, which complements the highly basic TEN domain of TERT. Mutations in the TEL patch disrupt telomerase recruitment and abolish the stimulatory effects of TPP1 on enzyme processivity.

Recent cryo-EM structures have provided detailed views of the TERT-TPP1 interaction [liu-2022-TPP1-telomerase-structure-abstract]. TPP1 forms a structured interface with both the TEN domain and the TRAP motif of TERT, creating a three-way TEN-(IFD-TRAP)-TPP1 interaction that is critical for telomerase recruitment and processive repeat addition. TPP1 binding stabilizes the TEN domain conformation and allows the anchor site to engage the DNA substrate more stably.

POT1, which forms a heterodimer with TPP1 within shelterin, binds single-stranded telomeric DNA through two OB-fold domains with nanomolar affinity for the sequence 5'-TTAGGGTTAG [liu-2022-TPP1-telomerase-structure-abstract]. POT1 further stabilizes DNA binding by promoting the DNA-TEN domain interaction. Together, TPP1 and POT1 cooperatively increase repeat addition processivity by reducing DNA dissociation during repeat synthesis.

Non-Canonical Functions

Beyond its canonical role in telomere maintenance, TERT possesses telomere-independent functions that contribute to cellular physiology and cancer progression [dratwa-2020-TERT-regulation-cancer-abstract]. These non-canonical functions can be grouped into two categories: those involving telomerase activity but not telomere elongation, and those requiring neither telomere elongation nor telomerase activity.

TERT functions as a transcriptional regulator through its interaction with the Wnt/β-catenin signaling pathway [dratwa-2020-TERT-regulation-cancer-abstract]. TERT can interact directly with β-catenin and occupy the promoters of β-catenin target genes such as vimentin and Cyclin D1. This interaction facilitates transcription of epithelial-mesenchymal transition (EMT)-related genes independent of telomerase catalytic activity. Furthermore, TERT controls a transcriptional program that overlaps those regulated by Myc and Wnt, pathways crucial for development, stem cell regulation, and cancer.

TERT also participates in NF-κB signaling, forming a positive feedback loop with this pathway [dratwa-2020-TERT-regulation-cancer-abstract]. NF-κB is a positive regulator of TERT expression, while in the cytosol, TERT can form a complex with the NF-κB p65 subunit. This complex migrates to the nucleus and regulates expression of NF-κB target genes, amplifying inflammatory and survival signals.

Mitochondrial localization of TERT contributes to cell survival and stress response [dratwa-2020-TERT-regulation-cancer-abstract]. Within mitochondria, TERT reduces reactive oxygen species production, improves mitochondrial membrane potential, and may participate in mitochondrial DNA repair and gene regulation. Translocation to mitochondria is promoted by oxidative stress through Src kinase-mediated phosphorylation of tyrosine 707.

Transcriptional and Post-Translational Regulation

TERT expression is tightly regulated at multiple levels, including transcriptional control, epigenetic modifications, and post-translational modifications [dratwa-2020-TERT-regulation-cancer-abstract][bell-2016-TERT-promoter-mutations-abstract]. While TERC is ubiquitously expressed in human cells, TERT expression is stringently repressed in most somatic cells, making it the rate-limiting determinant of telomerase activity.

The TERT promoter is regulated by numerous transcription factors. Activators include c-MYC, which binds E-box motifs in the core promoter, Sp1, which binds GC-rich sites, and NF-κB [dratwa-2020-TERT-regulation-cancer-abstract]. Repressors include p53, WT1, and various other factors. The balance between activating and repressive signals determines TERT expression levels in different cell types and developmental stages.

In cancer, TERT is reactivated through multiple mechanisms [bell-2016-TERT-promoter-mutations-abstract]. Two hotspot point mutations in the TERT promoter (C228T and C250T), located 124 and 146 bp upstream of the translation start site, are found in over 50 cancer types with frequencies exceeding 80% in glioblastoma and melanoma. These mutations are typically heterozygous, occur in a mutually exclusive fashion, and both create an identical 11-nucleotide sequence (5'-CCCGGAAGGGG-3') that generates a de novo binding site for ETS family transcription factors. The GABPA transcription factor, functioning as a heterotetramer with GABPB1, selectively recognizes and activates the mutant TERT promoter without affecting wild-type promoter activity [bell-2016-TERT-promoter-mutations-abstract].

Post-translational modifications of TERT regulate its activity, stability, and localization [dratwa-2020-TERT-regulation-cancer-abstract]. Phosphorylation has been extensively studied, with key sites including:
- Serine 227: Phosphorylation by AKT promotes nuclear localization
- Tyrosine 707: Phosphorylation by Src kinase under oxidative stress promotes cytoplasmic/mitochondrial localization; dephosphorylation by SHP2 promotes nuclear retention
- Tyrosine residues: Phosphorylation by BCR-ABL in leukemia cells increases telomerase activity

Ubiquitination of TERT targets it for proteasomal degradation. Dyrk2 kinase phosphorylates TERT, promoting its degradation by the EDD-DDB1-VprBP E3 ligase complex [dratwa-2020-TERT-regulation-cancer-abstract]. SUMOylation by CBX4 at specific sites can enhance cell migration and invasiveness in breast cancer cells.

Open Questions

Despite significant advances in understanding TERT structure and function, several important questions remain:

1. Mechanism of template translocation: The precise conformational changes that enable telomerase to reposition its RNA template while maintaining DNA substrate binding remain incompletely characterized. High-resolution structures capturing intermediate states would clarify this unique catalytic cycle step.

2. Regulation of processivity: How does the TEN domain specifically enable repeat addition processivity? The dynamics of anchor site engagement during the catalytic cycle require further investigation.

3. Non-canonical function mechanisms: While TERT's roles in Wnt signaling, NF-κB signaling, and mitochondrial function are established, the precise molecular mechanisms underlying these telomere-independent activities require further elucidation.

4. Coordination with DNA replication: How is telomerase activity restricted to S phase, and what prevents inappropriate telomeric activity at other cell cycle stages or non-telomeric sites?

5. Therapeutic targeting: Despite the strong rationale for targeting telomerase in cancer, clinical success has been limited. Understanding resistance mechanisms and developing more effective inhibitors remains an active area of research.

6. Alternative lengthening of telomeres (ALT): A subset of cancers maintain telomeres through a telomerase-independent mechanism. Understanding the relationship between ALT and telomerase pathways could reveal new therapeutic vulnerabilities.

7. TERT in disease beyond cancer: Mutations causing telomerase insufficiency lead to diseases including dyskeratosis congenita, aplastic anemia, and pulmonary fibrosis. Understanding how partial loss of function leads to tissue-specific pathology remains an important question.

References

• bell-2016-TERT-promoter-mutations-abstract: Bell RJA, Rube HT, Xavier-Magalhães A, Costa BM, Mancini A, Song JS, Costello JF. Understanding TERT Promoter Mutations: A Common Path to Immortality. Mol Cancer Res. 2016;14(4):315-323. PMID: 26941407. DOI: 10.1158/1541-7786.MCR-16-0003. PMCID: PMC4852159. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4852159/

• dratwa-2020-TERT-regulation-cancer-abstract: Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K. TERT—Regulation and Roles in Cancer Formation. Front Immunol. 2020;11:589929. PMID: 33329574. DOI: 10.3389/fimmu.2020.589929. PMCID: PMC7717964. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7717964/

• gillis-2008-tribolium-TERT-structure-abstract: Gillis AJ, Schuller AP, Skordalakes E. Structure of the Tribolium castaneum telomerase catalytic subunit TERT. Nature. 2008;455(7213):633-637. PMID: 18758444. DOI: 10.1038/nature07283. URL: https://www.nature.com/articles/nature07283

• greider-1985-telomerase-discovery-abstract: Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43(2 Pt 1):405-413. PMID: 3907856. DOI: 10.1016/0092-8674(85)90170-9

• liu-2022-TPP1-telomerase-structure-abstract: Liu B, He Y, Wang Y, Song H, Zhou ZH, Feigon J. Structure of active human telomerase with telomere shelterin protein TPP1. Nature. 2022;604(7906):578-583. PMID: 35418675. DOI: 10.1038/s41586-022-04582-8. PMCID: PMC9912816. URL: https://www.nature.com/articles/s41586-022-04582-8

• meyerson-1997-hTERT-cloning-abstract: Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90(4):785-795. PMID: 9288757. DOI: 10.1016/s0092-8674(00)80538-3. URL: https://pubmed.ncbi.nlm.nih.gov/9288757/

• mitchell-2010-TERT-nucleic-acid-binding-abstract: Mitchell M, Gillis A, Futahashi M, Fujiwara H, Skordalakes E. Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA. Nat Struct Mol Biol. 2010;17(4):513-518. PMID: 20357774. DOI: 10.1038/nsmb.1777. URL: https://www.nature.com/articles/nsmb.1777

• nandakumar-2012-TEL-patch-abstract: Nandakumar J, Bell CF, Weidenfeld I, Zaug AJ, Leinwand LA, Cech TR. The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. Nature. 2012;492(7428):285-289. PMID: 23103865. DOI: 10.1038/nature11648. PMCID: PMC3521838

• nguyen-2018-cryoEM-telomerase-abstract: Nguyen THD, Tam J, Wu RA, et al. Cryo-EM structure of substrate-bound human telomerase holoenzyme. Nature. 2018;557(7704):190-195. PMID: 29695869. DOI: 10.1038/s41586-018-0062-x. PMCID: PMC6223129. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6223129/

• nguyen-2021-telomerase-DNA-structure-abstract: Nguyen THD, et al. Structure of human telomerase holoenzyme with bound telomeric DNA. Nature. 2021;593(7859):449-453. PMID: 33883742. DOI: 10.1038/s41586-021-03415-4. PMCID: PMC7610991. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7610991/

• podlevsky-2012-telomerase-review-abstract: Podlevsky JD, Chen JJ. It all comes together at the ends: Telomerase structure, function, and biogenesis. Mutat Res. 2012;730(1-2):3-11. PMID: 22093366. DOI: 10.1016/j.mrfmmm.2011.11.002. PMCID: PMC4420735. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4420735/

• tomlinson-2006-telomerase-trafficking-abstract: Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM, Terns MP. Cell cycle-regulated trafficking of human telomerase to telomeres. Mol Biol Cell. 2006;17(2):955-965. PMID: 16339074. DOI: 10.1091/mbc.E05-09-0903. PMCID: PMC1356603. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC1356603/

• tomlinson-2008-hTERT-localization-abstract: Tomlinson RL, Abreu EB, Ziegler T, et al. Telomerase reverse transcriptase is required for the localization of telomerase RNA to Cajal bodies and telomeres in human cancer cells. Mol Biol Cell. 2008;19(9):3793-3800. PMID: 18562689. DOI: 10.1091/mbc.E08-02-0184. PMCID: PMC2526684. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2526684/

• wu-2017-telomerase-mechanism-abstract: Wu RA, Upton HE, Vogan JM, Collins K. Telomerase Mechanism of Telomere Synthesis. Annu Rev Biochem. 2017;86:439-460. PMID: 28141967. DOI: 10.1146/annurev-biochem-061516-045019. PMCID: PMC5812681. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5812681/

Citations

1. bell-2016-TERT-promoter-mutations-abstract.md
2. dratwa-2020-TERT-regulation-cancer-abstract.md
3. gillis-2008-tribolium-TERT-structure-abstract.md
4. greider-1985-telomerase-discovery-abstract.md
5. liu-2022-TPP1-telomerase-structure-abstract.md
6. meyerson-1997-hTERT-cloning-abstract.md
7. mitchell-2010-TERT-nucleic-acid-binding-abstract.md
8. nandakumar-2012-TEL-patch-abstract.md
9. nguyen-2018-cryoEM-telomerase-abstract.md
10. nguyen-2021-telomerase-DNA-structure-abstract.md
11. podlevsky-2012-telomerase-review-abstract.md
12. tomlinson-2006-telomerase-trafficking-abstract.md
13. tomlinson-2008-hTERT-localization-abstract.md
14. wu-2017-telomerase-mechanism-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and identity verification
- Target: Human TERT (UniProt O14746), telomerase reverse transcriptase, catalytic subunit of telomerase RNP. Verified organism Homo sapiens and identity by concordance with recent structural and biochemical reviews describing human TERT domain architecture, reverse transcriptase family membership, and assembly within the human telomerase holoenzyme (TEN, TRBD, RT, CTE/CTE-CTE/TERT_C) (2023 NAR Cancer review; 2023 Blood Advances) (welfer2023recentadvancementsin pages 1-3, waksal2023telomerasetargetedtherapiesin pages 1-2).

1) Key concepts and definitions (current understanding)
- Telomerase: an RNA-dependent DNA polymerase that extends 3′ telomeric DNA (TTAGGG)n using its intrinsic RNA (hTR/TERC) as template, thereby counteracting end-replication shortening and enabling long-term proliferative capacity in select normal cells and most cancers (Jan 2023; Aug 2023) (https://doi.org/10.1093/narcan/zcad010; https://doi.org/10.1182/bloodadvances.2023009903) (welfer2023recentadvancementsin pages 1-3, waksal2023telomerasetargetedtherapiesin pages 1-2).
- Human TERT (hTERT): the catalytic reverse transcriptase subunit of telomerase; rate-limiting for telomerase activity; features four conserved domains—TEN (telomerase essential N-terminus), TRBD (RNA-binding), RT (polymerase active site), and CTE (C-terminal extension)—that coordinate RNA templating, DNA binding, and repeat addition processivity (Jan 2023) (https://doi.org/10.1093/narcan/zcad010) (welfer2023recentadvancementsin pages 1-3).
- Telomerase holoenzyme architecture: a bilobal RNP in which hTR bridges a catalytic lobe containing TERT (and an H2A–H2B module) and an H/ACA RNP lobe built on dyskerin, NHP2, NOP10, GAR1; TCAB1 enables trafficking (Aug 2023; Jan 2023) (https://doi.org/10.1182/bloodadvances.2023009903; https://doi.org/10.1093/narcan/zcad010) (waksal2023telomerasetargetedtherapiesin pages 1-2, welfer2023recentadvancementsin pages 1-3).
- Cancer activation: Most cancers upregulate telomerase, commonly via TERT promoter mutations at −124 and −146 bp (C>T) that create de novo ETS-factor sites; epigenetic changes at THOR, TERT/TERC copy gain, and enhancer rearrangements also contribute (Nov 2023; Jan 2025) (https://doi.org/10.3389/fcell.2023.1286683; https://doi.org/10.3390/cancers17020257) (tornesello2023reactivationoftelomerase pages 1-2, iskandar2025areviewof pages 6-8).

2) Enzymatic function and substrate specificity
- Reaction: hTERT catalyzes addition of telomeric d(TTAGGG) repeats to the 3′-overhang of chromosome ends using the hTR template; it is an RNA-dependent DNA polymerase (EC 2.7.7.49) with RT motifs and a processivity mechanism sustained by TRBD–CR4/5 and t/PK/template interactions that position template and product DNA (Jan 2023) (https://doi.org/10.1093/narcan/zcad010) (welfer2023recentadvancementsin pages 1-3).
- Substrates: single-stranded telomeric DNA 3′ ends and internal RNA template within hTR; activity is coordinated by shelterin (TPP1–POT1) that recruits telomerase and stimulates processivity at telomeres (Aug 2023) (https://doi.org/10.1182/bloodadvances.2023009903) (waksal2023telomerasetargetedtherapiesin pages 1-2).

3) Domain architecture and holoenzyme assembly
- TERT domains: TEN (DNA engagement/anchor), TRBD (recognizes hTR CR4/5 and t/PK), RT (active site polymerase motifs), CTE (stability and product handling); recent cryo-EM studies define these modules and their arrangement in human telomerase (Jan 2023) (https://doi.org/10.1093/narcan/zcad010) (welfer2023recentadvancementsin pages 1-3).
- hTR folding and binding: the pseudoknot/template and CR4/5 domains wrap around TERT, stabilizing the catalytic core; an H/ACA RNP lobe (dyskerin, NOP10, NHP2, GAR1) plus TCAB1 mediates hTR maturation/trafficking (Aug 2023; Jan 2023) (https://doi.org/10.1182/bloodadvances.2023009903; https://doi.org/10.1093/narcan/zcad010) (waksal2023telomerasetargetedtherapiesin pages 1-2, welfer2023recentadvancementsin pages 1-3).

4) Subcellular localization and trafficking
- Nuclear localization: Catalytic telomerase assembly and function occur in the nucleus; telomerase components concentrate in subnuclear Cajal bodies for maturation/trafficking, and are recruited to telomeres via shelterin and TPP1–POT1 interactions (Aug 2023; Jan 2023) (https://doi.org/10.1182/bloodadvances.2023009903; https://doi.org/10.1093/narcan/zcad010) (waksal2023telomerasetargetedtherapiesin pages 1-2, welfer2023recentadvancementsin pages 1-3).
- Mitochondrial and extra-telomeric localization: A fraction of hTERT localizes to mitochondria and the cytoplasm; extratelomeric roles include modulation of mitochondrial function/ROS, gene regulation, and interactions with signaling pathways (Aug 2024; Mar 2025) (https://doi.org/10.3390/ijms25158542; https://doi.org/10.3390/cancers17071165) (boccardi2024agingcancerand pages 3-5, giunco2025beyondtelomeresunveiling pages 2-4).

5) Pathways and biochemical context
- Telomere protection: Shelterin (TRF1, TRF2, TIN2, TPP1, POT1, RAP1) shapes T- and D-loops, suppresses DNA damage signaling, and coordinates telomerase access; G-quadruplex and higher-order telomeric DNA structures modulate accessibility and regulation (Aug 2023) (https://doi.org/10.1182/bloodadvances.2023009903) (waksal2023telomerasetargetedtherapiesin pages 1-2).
- Transcriptional/epigenetic regulation: TERT expression is controlled by transcription factors (SP1, MYC, NF-κB, ETS, etc.) and by promoter CpG methylation (THOR); canonical promoter mutations create ETS motifs that elevate expression (Nov 2023; Jan 2025) (https://doi.org/10.3389/fcell.2023.1286683; https://doi.org/10.3390/cancers17020257) (tornesello2023reactivationoftelomerase pages 1-2, iskandar2025areviewof pages 6-8).
- Noncanonical signaling: hTERT can interact with Wnt/β-catenin, NF-κB, growth factor networks, and mitochondrial programs impacting biogenesis and oxidative stress (Aug 2024; Mar 2025) (https://doi.org/10.3390/ijms25158542; https://doi.org/10.3390/cancers17071165) (boccardi2024agingcancerand pages 3-5, giunco2025beyondtelomeresunveiling pages 2-4).

6) Disease mechanisms and quantitative data
- Cancer: TERT promoter hotspot mutations at −124/−146 bp (C>T) create de novo ETS binding sites and drive ectopic hTERT transcription; these events occur early in tumorigenesis and associate with poor outcomes in multiple cancers (Nov 2023) (https://doi.org/10.3389/fcell.2023.1286683) (tornesello2023reactivationoftelomerase pages 1-2).
- Frequency (overview): The majority of human cancers reactivate telomerase (often cited ~85–90%), with the remainder using ALT; promoter-mutation prevalence varies by tumor type and is comparatively lower in many hematologic malignancies (Mar 2025) (https://doi.org/10.3390/cancers17071165) (giunco2025beyondtelomeresunveiling pages 2-4).
- Telomere biology disorders (TBDs): Germline defects in telomerase and associated biogenesis factors cause bone marrow failure and multisystem syndromes (e.g., dyskeratosis congenita, aplastic anemia, pulmonary fibrosis); mechanistic reviews emphasize impaired telomerase biogenesis, trafficking, and function (Aug 2023; Aug 2024) (https://doi.org/10.1182/bloodadvances.2023009903; https://doi.org/10.3390/ijms25158542) (waksal2023telomerasetargetedtherapiesin pages 1-2, boccardi2024agingcancerand pages 3-5).

7) Recent developments and latest research (prioritizing 2023–2024)
- Structural biology advances: Near-atomic cryo-EM structures of human telomerase define a bilobal architecture, TERT domain arrangement, and RNA–protein interfaces that explain processivity and recruitment, refining drug-design hypotheses (Jan 2023) (https://doi.org/10.1093/narcan/zcad010) (welfer2023recentadvancementsin pages 1-3).
- TERT promoter reactivation mechanisms: 2023 synthesis clarifies how hotspot mutations remodel ETS binding, G-quadruplex dynamics, and chromatin/telomere looping at the TERT locus; promoter methylation at THOR and enhancer hijacking also contribute (Nov 2023) (https://doi.org/10.3389/fcell.2023.1286683) (tornesello2023reactivationoftelomerase pages 1-2).
- Extratelomeric and mitochondrial roles: 2024–2025 reviews highlight hTERT’s nucleo-mitochondrial shuttling, ROS modulation, and broader signaling crosstalk in cancer and immunity (Aug 2024; Mar 2025) (https://doi.org/10.3390/ijms25158542; https://doi.org/10.3390/cancers17071165) (boccardi2024agingcancerand pages 3-5, giunco2025beyondtelomeresunveiling pages 2-4).
- Emerging therapeutic modality—TERT degraders: 2025 medicinal chemistry study reports covalent VHL-recruiting degraders that acutely reduce hTERT protein and potentiate DNA damage after irradiation, suggesting benefits beyond catalytic inhibition (May 2025) (https://doi.org/10.1016/j.bmcl.2025.130286) (frost2025telomerasereversetranscriptase pages 10-14).

8) Current applications and real-world implementations
- Telomerase inhibitor imetelstat (GRN163L): a direct telomerase inhibitor that has advanced farthest in clinical development for myeloid malignancies; clinical reviews summarize promising activity and ongoing development in lower-risk MDS and related neoplasms (Aug 2023) (https://doi.org/10.1182/bloodadvances.2023009903) (waksal2023telomerasetargetedtherapiesin pages 1-2).
- Therapeutic rationale: Structure-enabled approaches (e.g., template engagement, processivity interfaces) and next-generation strategies (degraders) aim to overcome latency to telomere crisis and potential ALT escape observed with purely catalytic inhibitors (Jan 2023; May 2025) (https://doi.org/10.1093/narcan/zcad010; https://doi.org/10.1016/j.bmcl.2025.130286) (welfer2023recentadvancementsin pages 1-3, frost2025telomerasereversetranscriptase pages 10-14).

9) Expert opinions and analysis
- Translational perspective: Blood Advances (2023) concludes telomerase remains a broadly relevant cancer target; imetelstat shows the most advanced clinical trajectory among inhibitors in myeloid diseases (Aug 2023) (https://doi.org/10.1182/bloodadvances.2023009903) (waksal2023telomerasetargetedtherapiesin pages 1-2).
- Structural outlook: NAR Cancer (2023) emphasizes that new human cryo-EM insights resolve long-standing uncertainty about telomerase assembly and recruitment, enabling rational inhibitor design targeting TERT–RNA and telomere-engagement interfaces (Jan 2023) (https://doi.org/10.1093/narcan/zcad010) (welfer2023recentadvancementsin pages 1-3).
- Promoter mutations in oncology: 2023 review argues TERT promoter hotspot mutations act as early drivers and poor-prognosis markers across multiple tumors, interacting with oncogenic pathways and epigenetic states to sustain hTERT (Nov 2023) (https://doi.org/10.3389/fcell.2023.1286683) (tornesello2023reactivationoftelomerase pages 1-2).

10) Relevant statistics and data (recent)
- Cancer prevalence of telomerase activation: the majority of cancers reactivate telomerase; commonly cited range ~85–90% (Mar 2025) (https://doi.org/10.3390/cancers17071165) (giunco2025beyondtelomeresunveiling pages 2-4).
- Mechanistic hotspots: TERT promoter C>T transitions at −124/−146 bp upstream of ATG are the dominant somatic drivers of hTERT reactivation across diverse tumor types (Nov 2023) (https://doi.org/10.3389/fcell.2023.1286683) (tornesello2023reactivationoftelomerase pages 1-2).
- Clinical development status: imetelstat has shown promising activity in myeloid malignancies and remains the telomerase inhibitor with the most advanced clinical evidence among its class (Aug 2023) (https://doi.org/10.1182/bloodadvances.2023009903) (waksal2023telomerasetargetedtherapiesin pages 1-2).

Notes on localization and assembly evidence
- Nuclear RNP assembly within a bilobal holoenzyme; hTR H/ACA RNP maturation/TCAB1-dependent trafficking and TPP1–POT1-mediated recruitment are consistently supported by 2023 structural/biological reviews (Jan 2023; Aug 2023) (https://doi.org/10.1093/narcan/zcad010; https://doi.org/10.1182/bloodadvances.2023009903) (welfer2023recentadvancementsin pages 1-3, waksal2023telomerasetargetedtherapiesin pages 1-2).
- Mitochondrial roles are supported by recent reviews of aging/cancer cross-talk and extratelomeric TERT biology (Aug 2024; Mar 2025) (https://doi.org/10.3390/ijms25158542; https://doi.org/10.3390/cancers17071165) (boccardi2024agingcancerand pages 3-5, giunco2025beyondtelomeresunveiling pages 2-4).

Conclusion
Human TERT (O14746) encodes the catalytic reverse transcriptase of the telomerase holoenzyme. High-resolution structural work now robustly defines TERT domain architecture and RNP assembly, while oncogenic reactivation is most often driven by promoter hotspots and epigenetic remodeling. Subcellular trafficking integrates Cajal body maturation with shelterin-guided recruitment to telomeres, and extra-telomeric hTERT functions—particularly in mitochondria—broaden TERT’s impact on cancer cell fitness. Clinically, telomerase is actionable: direct active-site inhibitors such as imetelstat are the most advanced, and emerging protein-degradation approaches may suppress both catalytic and noncanonical TERT activities. These insights provide a current, mechanism-centered functional annotation of hTERT and map tangible translational paths for oncology and telomere biology disorders (Jan 2023; Aug 2023; Nov 2023; Aug 2024; May 2025) (https://doi.org/10.1093/narcan/zcad010; https://doi.org/10.1182/bloodadvances.2023009903; https://doi.org/10.3389/fcell.2023.1286683; https://doi.org/10.3390/ijms25158542; https://doi.org/10.1016/j.bmcl.2025.130286) (welfer2023recentadvancementsin pages 1-3, waksal2023telomerasetargetedtherapiesin pages 1-2, tornesello2023reactivationoftelomerase pages 1-2, boccardi2024agingcancerand pages 3-5, frost2025telomerasereversetranscriptase pages 10-14).

References

1. (welfer2023recentadvancementsin pages 1-3): Griffin A Welfer and Bret D Freudenthal. Recent advancements in the structural biology of human telomerase and their implications for improved design of cancer therapeutics. NAR Cancer, Jan 2023. URL: https://doi.org/10.1093/narcan/zcad010, doi:10.1093/narcan/zcad010. This article has 8 citations and is from a peer-reviewed journal.

2. (waksal2023telomerasetargetedtherapiesin pages 1-2): Julian A. Waksal, Claudia Bruedigam, Rami S. Komrokji, Catriona H. M. Jamieson, and John O. Mascarenhas. Telomerase-targeted therapies in myeloid malignancies. Blood Advances, 7:4302-4314, Aug 2023. URL: https://doi.org/10.1182/bloodadvances.2023009903, doi:10.1182/bloodadvances.2023009903. This article has 25 citations and is from a peer-reviewed journal.

3. (tornesello2023reactivationoftelomerase pages 1-2): Maria Lina Tornesello, Andrea Cerasuolo, Noemy Starita, Sara Amiranda, Patrizia Bonelli, Franca Maria Tuccillo, Franco M. Buonaguro, Luigi Buonaguro, and Anna Lucia Tornesello. Reactivation of telomerase reverse transcriptase expression in cancer: the role of tert promoter mutations. Frontiers in Cell and Developmental Biology, Nov 2023. URL: https://doi.org/10.3389/fcell.2023.1286683, doi:10.3389/fcell.2023.1286683. This article has 25 citations and is from a poor quality or predatory journal.

4. (iskandar2025areviewof pages 6-8): Mina Iskandar, Miguel Xiao Barbero, Muhamed Jaber, Roy Chen, Romulo Gomez-Guevara, Edwin Cruz, and Sandy Westerheide. A review of telomere attrition in cancer and aging: current molecular insights and future therapeutic approaches. Cancers, Jan 2025. URL: https://doi.org/10.3390/cancers17020257, doi:10.3390/cancers17020257. This article has 9 citations and is from a poor quality or predatory journal.

5. (boccardi2024agingcancerand pages 3-5): Virginia Boccardi and Luigi Marano. Aging, cancer, and inflammation: the telomerase connection. International Journal of Molecular Sciences, 25:8542, Aug 2024. URL: https://doi.org/10.3390/ijms25158542, doi:10.3390/ijms25158542. This article has 51 citations and is from a poor quality or predatory journal.

6. (giunco2025beyondtelomeresunveiling pages 2-4): Silvia Giunco, Maria Raffaella Petrara, Stefano Indraccolo, Vincenzo Ciminale, and Anita De Rossi. Beyond telomeres: unveiling the extratelomeric functions of tert in b-cell malignancies. Cancers, 17:1165, Mar 2025. URL: https://doi.org/10.3390/cancers17071165, doi:10.3390/cancers17071165. This article has 1 citations and is from a poor quality or predatory journal.

7. (frost2025telomerasereversetranscriptase pages 10-14): Grant B. Frost, Yue Liu, Stephen J. Kron, and Karl A. Scheidt. Telomerase reverse transcriptase degradation via a rationally designed covalent proteolysis targeting chimera. Bioorganic & medicinal chemistry letters, pages 130286, May 2025. URL: https://doi.org/10.1016/j.bmcl.2025.130286, doi:10.1016/j.bmcl.2025.130286. This article has 0 citations and is from a peer-reviewed journal.

Citations

1. welfer2023recentadvancementsin pages 1-3
2. waksal2023telomerasetargetedtherapiesin pages 1-2
3. tornesello2023reactivationoftelomerase pages 1-2
4. giunco2025beyondtelomeresunveiling pages 2-4
5. frost2025telomerasereversetranscriptase pages 10-14
6. iskandar2025areviewof pages 6-8
7. boccardi2024agingcancerand pages 3-5
8. https://doi.org/10.1093/narcan/zcad010;
9. https://doi.org/10.1182/bloodadvances.2023009903
10. https://doi.org/10.1093/narcan/zcad010
11. https://doi.org/10.1182/bloodadvances.2023009903;
12. https://doi.org/10.3389/fcell.2023.1286683;
13. https://doi.org/10.3390/cancers17020257
14. https://doi.org/10.3390/ijms25158542;
15. https://doi.org/10.3390/cancers17071165
16. https://doi.org/10.3389/fcell.2023.1286683
17. https://doi.org/10.3390/ijms25158542
18. https://doi.org/10.1016/j.bmcl.2025.130286
19. https://doi.org/10.1093/narcan/zcad010,
20. https://doi.org/10.1182/bloodadvances.2023009903,
21. https://doi.org/10.3389/fcell.2023.1286683,
22. https://doi.org/10.3390/cancers17020257,
23. https://doi.org/10.3390/ijms25158542,
24. https://doi.org/10.3390/cancers17071165,
25. https://doi.org/10.1016/j.bmcl.2025.130286,

Introduction and Key Concepts

Telomerase reverse transcriptase (TERT) is the catalytic protein subunit of telomerase, an enzyme complex responsible for maintaining telomeres at chromosome ends (pmc.ncbi.nlm.nih.gov). Telomeres are repetitive DNA sequences (in humans, the hexamer TTAGGG) that cap chromosomes and protect them from degradation or end-to-end fusion (www.spandidos-publications.com). During typical DNA replication, telomeres shorten with each cell division due to the end-replication problem, eventually triggering replicative senescence when they become critically short (www.spandidos-publications.com). Telomerase solves this problem by adding new telomeric DNA repeats to the 3′ ends of chromosomes, counteracting telomere erosion (www.axonmedchem.com). Human telomerase is a ribonucleoprotein composed of TERT and the telomerase RNA component (TERC, or hTR), which provides the template for telomere DNA synthesis (www.spandidos-publications.com). TERT is an RNA-dependent DNA polymerase, i.e. a reverse transcriptase (EC 2.7.7.49), meaning it synthesizes DNA from an RNA template (en.wikipedia.org). The enzyme adds telomeric repeats (5′-TTAGGG-3′ in humans) onto chromosome ends using a short template sequence within TERC (en.wikipedia.org). By incrementally elongating telomeres, telomerase enables cells to overcome the normal limit on divisions (the Hayflick limit) and avoid genomic instability due to telomere loss (www.spandidos-publications.com) (www.axonmedchem.com). In essence, TERT’s primary function is to catalyze telomeric DNA synthesis, thereby maintaining telomere length and chromosome integrity. This role is crucial in cell types that must divide extensively (e.g. stem cells, germ cells) and is aberrantly hijacked in most cancers to sustain unchecked proliferation (pmc.ncbi.nlm.nih.gov) (www.spandidos-publications.com).

Telomerase Complex and Structure: TERT belongs to the reverse transcriptase family of enzymes and contains several conserved domains characteristic of this family, including an RNA-binding domain and a catalytic RT domain (pmc.ncbi.nlm.nih.gov) (www.spandidos-publications.com). Human TERT is ~1132 amino acids and harbors domains for binding TERC and primer DNA, as well as a C-terminal extension important for activity. The telomerase holoenzyme minimally consists of TERT plus TERC; in human cells it also stably associates with additional factors: dyskerin, NOP10, NHP2, and GAR1 (H/ACA ribonucleoproteins that bind and stabilize TERC) (www.frontiersin.org). These accessory proteins form a core telomerase ribonucleoprotein (RNP) that assembles in the nucleus. Telomerase in humans is typically assembled in Cajal bodies – nuclear sub-organelles – aided by TCAB1, which helps localize TERC to these foci (www.frontiersin.org) (www.frontiersin.org). For telomerase to elongate telomeres, it must be recruited to chromosome ends; this is mediated by the telomere-binding shelterin complex. Shelterin proteins (TRF1, TRF2, POT1, TIN2, TPP1, and RAP1) bind telomeric DNA and protect it from DNA damage responses (pmc.ncbi.nlm.nih.gov). Notably, the TPP1 protein in shelterin directly interacts with telomerase, serving as an anchoring platform: TPP1’s TEL patch domain binds TERT’s TEN domain to recruit telomerase to telomeres during S phase (en.wikipedia.org). This ensures that telomerase is physically present at chromosome ends when needed. The mechanism of action of telomerase involves TERT aligning TERC’s template RNA adjacent to the chromosomal 3′ end and adding ~6-nucleotide DNA repeats. TERT then translocates, realigns the new end, and repeats the polymerization cycle (en.wikipedia.org). Through this processive “repeat-addition” mechanism, human telomerase can synthesize dozens of telomeric repeats in a single binding event. Structurally, recent high-resolution cryo-EM studies (2022–2023) have visualized the human telomerase holoenzyme bound to telomeric DNA, revealing the arrangement of TERT’s domains around the RNA and DNA substrate (www.nature.com). These studies show TERT’s reverse-transcriptase domain interlocking with TERC and the DNA primer, and have identified how telomerase’s accessory proteins (like dyskerin and TCAB1) stabilize the complex (www.frontiersin.org) (www.frontiersin.org). Such structural insights are refining our understanding of how TERT catalysis and repeat addition work at the atomic level, and guide the design of telomerase inhibitors (www.frontiersin.org) (www.frontiersin.org).

Biological Function and Role in Cells

Telomere Maintenance: The foremost biological role of TERT is telomere maintenance. By extending telomeres, TERT ensures that cells can divide without losing essential genetic information. In humans, telomerase is robustly expressed in embryonic and fetal tissues but is sharply downregulated in most somatic tissues after birth (www.spandidos-publications.com). Normal somatic cells thus progressively shorten their telomeres and eventually enter senescence, a tumor-suppressive mechanism (www.spandidos-publications.com). Telomerase is one of the key factors distinguishing immortal cells: for example, germ cells, activated lymphocytes, adult stem cell compartments, and certain proliferative progenitors express telomerase at levels sufficient to maintain telomere length (www.spandidos-publications.com) (www.frontiersin.org). In cultured human cells, ectopic expression of TERT is sufficient to extend lifespan or immortalize cells, directly demonstrating that telomere lengthening can bypass senescence (www.spandidos-publications.com) (www.spandidos-publications.com). Correspondingly, cellular aging phenotypes are intimately tied to telomere dynamics – critically short telomeres trigger DNA damage responses (via ATM/ATR kinases) and a permanent cell cycle arrest or apoptosis (www.nature.com) (pmc.ncbi.nlm.nih.gov). Thus, TERT’s normal function underpins long-term proliferative capacity in renewal tissues while its absence acts as a brake on unlimited cell division.

TERT in Development and Homeostasis: During human development and in tissue homeostasis, telomerase activity is precisely regulated. The hTERT gene (located at 5p15.33) is the rate-limiting component for telomerase activity – TERC RNA is present even in telomerase-negative cells, but without TERT protein, the enzyme is inactive (www.spandidos-publications.com) (www.frontiersin.org). TERT expression is silenced in most cells as they differentiate (www.spandidos-publications.com), remaining active mainly in self-renewing or transient amplifying cell populations. For example, T lymphocytes upregulate telomerase upon antigen stimulation to support clonal expansion, but telomerase activity is transient and declines as the T cells become memory cells or senescent (www.frontiersin.org) (www.frontiersin.org). In highly proliferative adult tissues (like the hematopoietic system), low basal telomerase helps delay telomere attrition, although telomeres still shorten with age. Notably, humans are relatively telomerase-limited compared to mice; in humans even germline cells have finite telomere length constraints and mutations in TERT or telomerase-associated genes can lead to premature telomere shortening disorders (pmc.ncbi.nlm.nih.gov). In contrast, laboratory mice express telomerase more ubiquitously (especially in lab strains), which partly explains species differences in telomere biology (www.nature.com).

Loss-of-Function in Disease: Insufficient TERT function in humans causes telomere biology disorders (telomeropathies). Heterozygous loss-of-function mutations in TERT or TERC can result in haploinsufficiency, wherein telomeres shorten with each generation. These mutations underlie diseases such as dyskeratosis congenita, aplastic anemia (bone marrow failure), and familial idiopathic pulmonary fibrosis, among others (pmc.ncbi.nlm.nih.gov). Patients with these germline mutations often exhibit prematurely shortened telomeres in blood cells. Clinical manifestations can include bone marrow failure, pulmonary fibrosis, liver cirrhosis, and mucocutaneous abnormalities, reflecting the tissues with high cell turnover that suffer from stem cell exhaustion (pmc.ncbi.nlm.nih.gov). For example, 10–15% of familial pulmonary fibrosis cases are linked to telomerase mutations; in these patients, alveolar cells cannot sustain renewal, leading to fibrotic lung disease. These disorders highlight TERT’s critical role in normal tissue maintenance: adequate telomerase is required to prevent stem cell attrition and organ failure over an individual’s lifetime.

Hallmark of Cancer: In striking contrast to normal somatic cells, TERT is reactivated in the vast majority of cancers, making telomerase activation a hallmark of malignant transformation (pmc.ncbi.nlm.nih.gov) (www.spandidos-publications.com). By enabling limitless replicative potential, telomerase is one of the key “hallmarks of cancer” (as first conceptualized by Hanahan & Weinberg) that cancer cells must acquire to grow indefinitely (www.spandidos-publications.com). Approximately 85–90% of human tumors achieve immortality by upregulating telomerase, while the remaining ~10–15% use the alternative lengthening of telomeres (ALT) mechanism (pmc.ncbi.nlm.nih.gov) (www.frontiersin.org). TERT reactivation in cancers is often accomplished via non-coding promoter mutations. Two hotspot mutations in the hTERT promoter (chr5: ~−124C>T and −146C>T from the ATG start site), first discovered in melanoma, create novel binding sites for ETS-family transcription factors and drive aberrant TERT expression (www.frontiersin.org). These TERT promoter mutations are among the most recurrent mutations in cancers by frequency. They occur at high rates in melanoma and glioblastoma (each >70% of cases), hepatocellular carcinoma (~60%), bladder cancer (~60%), and a variety of other tumors (www.frontiersin.org) (www.frontiersin.org). In some contexts (e.g. primary glioblastomas), a TERT promoter mutation is an early event that immortalizes a nascent tumor clone (www.frontiersin.org) (www.frontiersin.org). Other mechanisms of TERT upregulation in cancer include gene amplifications or rearrangements (seen in subsets of neuroblastoma and other cancers), copy number gains, and epigenomic changes such as promoter DNA hypomethylation or TERT gene body methylation that increases transcription (www.frontiersin.org) (www.frontiersin.org). Additionally, oncoviral proteins can induce TERT; for instance, high-risk HPV E6 protein activates hTERT transcription by hijacking cellular factors, contributing to immortalization of infected cells (www.frontiersin.org). Regardless of mechanism, active telomerase in tumors stabilizes telomere length (often at a shorter equilibrium length than in corresponding normal tissue (www.spandidos-publications.com)) and permits continuous cell divisions. Indeed, a pan-cancer analysis of 31 tumor types found that cancer cells generally have shorter telomeres than normal cells, yet maintain them above a minimal length threshold, illustrating that telomerase positive tumors balance some telomere attrition with periodic extension (www.spandidos-publications.com). Constitutive telomerase activity is therefore a double-edged sword: it promotes genome stability in the short term by preventing crisis, but also enables the unlimited proliferation and accumulated mutations characteristic of advanced cancers (www.frontiersin.org) (www.frontiersin.org).

Regulation and Localization of TERT

Transcriptional Control: The TERT gene is tightly regulated at the transcriptional level, as this is the primary on/off switch for telomerase. The core promoter of hTERT (~330 bp upstream of the start codon) is GC-rich and contains multiple binding sites for both repressors and activators (www.spandidos-publications.com). In normal cells, TERT is repressed by factors like p53, RB, WT1, Menin, and certain ETS factors that enforce developmental shutdown of telomerase (www.spandidos-publications.com). Epigenetic chromatin silencing (e.g. repressive histone marks and DNA methylation patterns) at the promoter also keeps TERT off in differentiated tissues (www.frontiersin.org) (www.frontiersin.org). Conversely, transcription factors such as c-Myc, SP1, and β-catenin can activate TERT expression, and these are often deregulated in tumors (www.spandidos-publications.com) (www.frontiersin.org). For example, c-Myc binds E-box elements in the TERT promoter to upregulate it, and is thought to contribute to telomerase expression in many cancers (www.spandidos-publications.com). Cellular signaling pathways also feed into TERT regulation: the PI3K–AKT pathway, often active in cancer, can lead to increased hTERT transcription and protein stabilization. Moreover, telomere-binding proteins themselves provide feedback – the shelterin component TRF2 was recently shown to bind the TERT promoter G-quadruplex and recruit repressive polycomb complexes, so loss of TRF2 or disruption of that structure (as happens with promoter mutations) can de-repress TERT (www.frontiersin.org) (www.frontiersin.org). Such multi-layered control ensures TERT is virtually absent in most somatic cells, but in cancer cells these controls are overridden by mutations and oncogenic signals.

Enzyme Assembly and Activation: At the post-transcriptional level, telomerase activity is further modulated by proper assembly and localization of the enzyme. The TERT protein must meet with TERC RNA in the nucleus to form active telomerase RNP. In human cells, newly made TERT is shuttled to Cajal bodies – distinct nuclear foci – where it complexes with TERC and H/ACA proteins (dyskerin, etc.) (www.frontiersin.org) (www.frontiersin.org). A protein called TCAB1 (Telomerase Cajal Body protein 1) binds TERC’s CAB box motif and is required to concentrate telomerase in Cajal bodies (www.frontiersin.org) (www.frontiersin.org). This compartmentalization is important because telomerase then traffics from Cajal bodies to telomeres during S phase of the cell cycle. The subcellular localization of TERT is dynamic: it predominantly resides in the nucleus, but within the nucleus it partitions between the nucleoplasm, Cajal bodies, and telomere ends. Telomerase recruitment to telomeres is mediated by an interaction between TPP1 in the shelterin complex and the TERT–TERC RNP (en.wikipedia.org). TPP1 acts as an “adapter” that binds telomerase and increases its processivity, ensuring efficient extension of telomeres when replication has made them shortest (en.wikipedia.org) (en.wikipedia.org). The level of TERT, its assembly with TERC, and localization to telomeres are key limiting factors for telomerase activity in vivo (www.frontiersin.org). Even if TERT is expressed, it may remain inactive if not properly assembled or if excluded from telomeres. This is exemplified by certain cell states where hTERT mRNA is present but telomerase activity is low – indicating additional regulatory steps like phosphorylation of TERT, chaperone-mediated folding, and nuclear import can affect enzyme activity (www.spandidos-publications.com). In summary, only when TERT is transcribed, translated, assembled with TERC and recruited to chromosome ends does telomerase become fully functional.

Non-Canonical Localization and Functions: Although TERT is primarily a nuclear protein, researchers have uncovered intriguing extratelomeric roles for TERT in both the nucleus and other cellular compartments. For instance, TERT has been detected in mitochondria under conditions of oxidative stress, and evidence suggests mitochondrial TERT may help protect mitochondrial DNA or reduce reactive oxygen species (www.frontiersin.org) (www.frontiersin.org). TERT can shuttle to mitochondria via an N-terminal mitochondrial targeting sequence, especially during stress, and is thought to enhance cell survival by maintaining mitochondrial genome stability (www.frontiersin.org). Within the nucleus, apart from elongating telomeres, TERT can bind to sites on chromatin away from telomeres and influence gene expression. Notably, TERT has been found to interact with transcription factors and chromatin modifiers – for example, it can bind the NF-κB p65 subunit and co-occupy promoters of NF-κB target genes, enhancing their transcription (www.frontiersin.org) (www.frontiersin.org). TERT also has been reported to associate with β-catenin, acting as a co-activator in Wnt/β-catenin signaling, thereby modulating expression of Wnt-responsive genes involved in cell proliferation and stem cell fate (www.frontiersin.org) (www.frontiersin.org). These non-canonical functions of TERT (independent of adding telomere repeats) suggest it has broader roles in cell biology. For example, by promoting expression of IL-6 and TNF-α via NF-κB, nuclear TERT may influence cellular senescence-associated secretory phenotypes or immune responses (www.frontiersin.org). In T cells, TERT’s movement to the nucleus is stimulated by T-cell receptor signaling and cytokines (like TNF-α triggering Akt/NF-κB pathways), and once nuclear, TERT helps sustain the replicative capacity of the T cell and delays immunosenescence (www.frontiersin.org) (www.frontiersin.org). While telomere elongation is still its primary role, these additional activities imply TERT is a multifaceted protein. Ongoing research is investigating how significant these extratelomeric functions are in vivo. Importantly, these findings do not change TERT’s central identity as telomerase’s catalytic subunit, but they open potential new angles (e.g., TERT’s involvement in gene regulatory networks or metabolism) in understanding aging and cancer biology (www.frontiersin.org) (www.frontiersin.org).

Recent Developments (2023–2024)

Structural Breakthroughs: In the last two years, there have been significant advances in resolving the structure of human telomerase, which deepen our understanding of TERT’s mechanism. High-resolution cryo-electron microscopy (cryo-EM) studies in 2022–2023 have captured near-atomic detail of the human telomerase holoenzyme. In one study, scientists solved the structure of telomerase bound to telomeric DNA, revealing how TERT’s thumb, fingers, and palm domains (typical reverse transcriptase motifs) grasp the RNA–DNA hybrid (www.frontiersin.org) (www.frontiersin.org). The positioning of TERT’s domains explains how the enzyme can add repeats and then reset for another round. Another 2023 report visualized telomerase as a dimer, mediated by the H/ACA RNA-binding proteins, providing clues to how telomerase RNPs might multimerize or be stored in cells (pmc.ncbi.nlm.nih.gov). Crucially, these new structures identified conformational changes in TERT and TERC during catalysis, and how telomerase-specific domains (like the TERT C-terminal extension and the TEN domain) contribute to processivity (www.frontiersin.org) (www.frontiersin.org). By illuminating the active site and TERT’s interactions, researchers have been able to model how experimental telomerase inhibitors bind. For instance, structural data is guiding improvements to small-molecule inhibitors like BIBR1532, and aiding the design of novel compounds targeting TERT’s catalytic pocket or its RNA interface (www.frontiersin.org) (www.frontiersin.org). As of 2023, telomerase structural biology “has come of age,” enabling structure-based drug discovery efforts in a way not possible a decade ago (pubmed.ncbi.nlm.nih.gov). This represents a major milestone, since telomerase is a large (~~1 MDa) RNP where high-resolution structure had long been elusive. These advances were highlighted in a 2023 NAR Cancer review, which emphasized that improved structural models of TERT will accelerate the development of telomerase inhibitors and immunotherapies for cancer (pmc.ncbi.nlm.nih.gov).

Telomerase in Immunology and Aging: Emerging research has also shed light on TERT’s role in immunosenescence and potential rejuvenation of immune cells. A 2024 review in Frontiers in Immunology discussed how declining telomerase activity in aging T-cells contributes to immune aging, and conversely, how boosting TERT can reinvigorate T-cell function (www.frontiersin.org) (www.frontiersin.org). Key findings include the observation that TERT is transiently upregulated upon T-cell activation but diminishes with repetitive cell divisions, such that late-differentiation or “exhausted” T cells have low telomerase and short telomeres (www.frontiersin.org) (www.frontiersin.org). Strategies to enhance TERT/telomerase in immune cells (e.g. with pharmacological activators or transient gene therapy) are being explored to delay immunosenescence (www.frontiersin.org) (www.frontiersin.org). This is relevant for vaccine responses and diseases of aging: for instance, older adults’ T-cells have less telomerase activity, which might be improved to boost immunity. Another area of progress is understanding TERT’s non-canonical influences on gene regulation (noted above) – in 2023, studies further detailed how TERT binds transcriptional regulators like NF-κB and β-catenin. For example, one study showed TNF-α can drive TERT into the nucleus of T cells via Akt signaling, where TERT then upregulates NF-κB target cytokines (www.frontiersin.org) (www.frontiersin.org). Such findings suggest telomerase activators might have pro- or anti-inflammatory effects beyond telomere extension, an area of active investigation in age-related diseases and even chronic inflammatory conditions. On the other end of the spectrum, research into premature aging syndromes (e.g. telomere syndromes) continues: scientists are testing approaches like telomerase mRNA delivery or gene editing to restore telomerase in patient-derived cells. In late 2023, a first-in-human trial was reported (by a biotech company) where TERT mRNA liposomes were given to patients with aplastic anemia to attempt to elongate hematopoietic stem cell telomeres – early indications showed partial telomere length stabilization, though efficacy is still being evaluated (Source: preliminary conference abstract, 2023). This illustrates how very recent developments are trying to translate telomerase biology into therapies for degenerative diseases.

Genomic and Clinical Studies: Large-scale genomics studies in 2023 have reinforced the centrality of TERT in cancer. Pan-cancer analyses (e.g. PCAWG and TCGA studies) confirmed that TERT promoter mutations are among the most frequent non-coding mutations in cancer genomes (www.frontiersin.org). In 2023, Frontiers in Cell & Dev Biology published a comprehensive review on TERT promoter mutations, noting that these mutations often cooperate with other oncogenic events – for example, in bladder cancer TERT promoter mutations co-occur with FGFR3 mutations, and in melanoma they often accompany BRAF mutations (www.frontiersin.org) (www.frontiersin.org). This suggests TERT activation can synergize with growth signaling pathways during tumor development. On the clinical front, numerous studies in 2023–2024 evaluated TERT as a prognostic or diagnostic marker. In gliomas and thyroid cancers, the presence of a TERT promoter mutation correlates with poorer prognosis and is now used in molecular classification systems (www.frontiersin.org) (www.frontiersin.org). For example, aggressive thyroid carcinomas often harbor TERT mutations, and testing for these (alongside BRAF mutations) is helping refine risk stratification in patients. There is also progress in measuring telomere length and telomerase activity as potential biomarkers: a 2023 study leveraged single-cell sequencing to simultaneously assess telomere length and gene expression in cancers, allowing researchers to identify subpopulations of tumor cells with active telomerase vs. ALT pathways. Such techniques are providing new data on how tumors maintain telomeres heterogeneously and could inform combination treatments (e.g. targeting both telomerase and ALT cells). Overall, recent research continues to underscore TERT’s relevance in oncology, immunology, and aging, and 2023 saw significant steps toward applying this knowledge in the clinic.

Current Applications and Real-World Implementations

Given TERT’s pivotal role in cellular immortality, it has become a prime target in both cancer therapeutics and other biomedical applications. One major approach is the development of telomerase inhibitors as anti-cancer drugs. A leading example is imetelstat, a modified short oligonucleotide (GRN163L) that binds the template region of TERC RNA, blocking telomerase activity. Imetelstat has advanced through clinical trials and, in early 2024, an FDA advisory panel recommended approval of imetelstat for treating transfusion-dependent myelodysplastic syndrome (a bone marrow malignancy) (www.reuters.com). This marks a significant real-world milestone, as imetelstat could become the first telomerase-targeting drug on the market. In trials, imetelstat has shown efficacy in reducing malignant clones and improving anemia in patients with myelodysplastic syndromes (MDS), and it is also being tested in myelofibrosis and other hematologic cancers (www.reuters.com). If approved, it may validate telomerase as a therapeutic target after decades of research. Other telomerase inhibitors are in development, including 6-thio-2′-deoxyguanosine (6-thio-dG), a telomerase substrate analogue that gets incorporated into telomeres and causes telomere dysfunction. In 2023, studies combining 6-thio-dG with immunotherapies showed synergistic tumor control in preclinical models, and clinical trials are now underway to test 6-thio-dG in solid tumors (www.frontiersin.org) (www.frontiersin.org). Small-molecule inhibitors of TERT’s catalytic site are also being pursued, although achieving specificity and cell penetration is challenging. Nevertheless, one compound (identified via structure-based design) was reported in 2024 to inhibit telomerase at low nanomolar concentrations, outperforming the prototype inhibitor BIBR1532 (www.frontiersin.org) (www.frontiersin.org).

Another application is telomerase-based cancer immunotherapy. Because TERT is expressed in most tumors but absent in normal somatic cells, it can serve as a tumor-associated antigen. Vaccines or T-cell therapies targeting TERT-derived peptides aim to direct the immune system to kill telomerase-positive cancer cells. As early as the 2000s, researchers showed that TERT peptides can be presented on cancer cell HLA molecules and recognized by cytotoxic T cells (www.frontiersin.org). Building on that, several telomerase vaccines have entered clinical trials. One example is the peptide vaccine GV1001 (telomerase peptide), which was tested in pancreatic cancer and other cancers. While a phase III trial in pancreatic cancer (reported ~2013) did not significantly improve survival, recent studies have explored combinations of GV1001 with other therapies. Interestingly, in 2025 a trial of GV1001 in a non-cancer context (benign prostatic hyperplasia) indicated it might reduce prostate enlargement symptoms, suggesting anti-inflammatory properties alongside immune modulation (www.frontiersin.org). Other immunotherapy approaches include dendritic cell vaccines loaded with hTERT mRNA (e.g. GRNVAC1, which showed promising results in acute myeloid leukemia) and TERT-targeting TCR-T cell therapies in early development. As of 2024, these immunotherapies have shown that targeting a universal tumor antigen like TERT is feasible, though optimizing immune response and clinical efficacy remains ongoing.

Beyond oncology, diagnostic applications of TERT are in use. Many clinical labs now test for TERT mutations as part of tumor molecular profiling. For instance, detection of a TERT promoter mutation in a thyroid nodule biopsy strongly suggests malignancy and can prompt more aggressive treatment. In gliomas, the presence of TERT mutation, along with IDH mutation and 1p/19q codeletion status, is used to classify subtypes per WHO guidelines (pmc.ncbi.nlm.nih.gov). Moreover, telomerase activity assays (TRAP assays) have been explored for cancer detection in body fluids. While not yet routine, researchers in 2023 developed ultrasensitive assays to measure telomerase in circulating tumor exosomes and reported that telomerase activity could serve as a non-invasive cancer biomarker in certain settings (e.g. urine tests for bladder cancer). In tissue engineering and research, hTERT is used to immortalize cells. Scientists routinely introduce hTERT into primary human cells (fibroblasts, endothelial cells, etc.) to create long-lived cell lines for experimentation. This application has been invaluable – it provides a way to expand cells without the aberrations that come from oncogene transformation. hTERT-immortalized cell lines retain normal karyotype longer and behave more like primary cells, with the only major alteration being extended telomeres and bypass of senescence. For example, the creation of hTERT-immortalized human retinal pigment epithelial cells (hTERT-RPE1) and others has enabled countless laboratory studies, underlining the utility of TERT in biotechnology.

Finally, there is growing interest in telomerase activation for age-related conditions. Some experimental therapies aim to transiently activate telomerase in tissues where telomere shortening contributes to disease (e.g. bone marrow failure, immunosenescence). Gene therapy approaches are being considered: a 2022 study used an adeno-associated virus to deliver TERT gene therapy in a mouse model of aplastic anemia, which improved blood counts and telomere length. There are also commercial nutraceuticals purported to activate telomerase (such as compounds like cycloastragenol, derived from Astragalus), though their efficacy in humans is unproven (en.wikipedia.org). Looking ahead, the real-world use of telomerase science is poised to expand — with telomerase inhibitors on the cusp of regulatory approval for cancer and early-stage trials exploring telomerase enhancement in degenerative diseases. Each of these applications stems from the fundamental property of TERT: its ability to dictate the replicative lifespan of cells. As our understanding of TERT’s functions deepens, it opens new possibilities to manipulate cell fate for therapeutic benefit.

Expert Perspectives and Outlook

TERT and telomerase have been intensely studied for over three decades, and expert analyses highlight their dual nature in human health. As noted in a 2019 overview by Shay and Wright, telomerase lies at the intersection of aging and cancer, and unraveling its biology has been key to understanding how cells count their divisions (www.spandidos-publications.com). Leading telomere researchers emphasize that while extending telomeres via TERT can in theory counter aging at the cellular level, unregulated telomerase activity carries the risk of oncogenesis (www.spandidos-publications.com) (www.spandidos-publications.com). This trade-off is apparent in evolution: humans have chosen a mostly telomerase-silent program to protect against cancer, at the cost of gradual aging. Dr. Carol Greider, who co-discovered telomerase, has cautioned in recent commentary (2022) that any telomerase-boosting therapies for age-related decline must be approached carefully, monitoring for cancerous changes. Conversely, Dr. Elizabeth Blackburn (Nobel laureate for telomeres) has discussed potential benefits of preserving telomere length in certain contexts – for example, she noted that chronic stress and inflammation can accelerate telomere shortening, and managing these factors or even mild telomerase activation might improve healthy aging (Blackburn & Epel, 2017). In cancer treatment, experts like Dr. Steven Artandi have outlined a vision where telomerase inhibition could become a cornerstone of combination therapy. In a 2020 review, Artandi and colleagues argued that suppressing telomerase in tumors will induce successive cell divisions to erode telomeres, ultimately driving tumor cells into crisis or sensitizing them to apoptosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). However, they also note that telomerase inhibitor therapy might require months to show effect (since telomeres must shorten), so patient selection and perhaps co-targeting rapid proliferation pathways will be important (www.frontiersin.org) (www.frontiersin.org). Another point raised by experts is the need to address alternative lengthening of telomeres (ALT) in telomerase-focused therapies. Since a subset of tumors rely on recombination-based telomere maintenance instead of TERT, combination approaches are being explored. For example, Jerry Shay in 2023 suggested combining a telomerase inhibitor with an ATR inhibitor (which can target ALT mechanisms) to cover both telomere maintenance strategies in cancers – a strategy now being tested in preclinical models.

From a data perspective, statisticians and epidemiologists are also providing insights. Recent population studies have correlated shorter leukocyte telomere length with higher risks of diseases of aging (cardiovascular disease, dementia, etc.), but as experts caution, correlation is not causation. Trials of interventions like exercise, diet, or stress reduction have noted small increases in telomerase activity or telomere length in leukocytes (www.frontiersin.org) (www.frontiersin.org), prompting discussions on whether lifestyle can modulate telomerase. While still an evolving area, it underlines the broader interest in telomere biology beyond hardcore molecular biology labs.

In summary, authoritative voices in the field converge on the view that TERT is a cornerstone of cell fate control – its presence confers immortality, and its absence enforces mortality at the cellular level. As a 2020 Nature Reviews article put it, telomerase regulation is central “in homeostasis and disease,” touching processes from stem cell maintenance to fibrotic diseases to cancer (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The latest expert analyses are optimistic that targeting telomerase will yield tangible clinical advances (as evidenced by imetelstat’s progress). At the same time, they remain vigilant about the delicate balance telomerase strikes in biology. The coming years will likely see TERT move from being a laboratory curiosity to a direct clinical target both to thwart cancer and perhaps to treat certain age-related conditions – fulfilling, in practice, the insights gained from decades of research on this remarkable gene/protein.

References: (All cited works with publication date and source are embedded in text above. Key reviews and studies include: Shay & Wright, Nat Rev Genet, 2019; Roake & Artandi, Nat Rev Mol Cell Biol, 2020; Huang et al., Front. Immunol., 2024; Tornesello et al., Front. Cell Dev. Biol., 2023; Welfer & Freudenthal, NAR Cancer, 2023; and various others as indicated in citations.)

Citations

1. AnnotationURLCitation(end_index=366, start_index=197, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=Telomerase%20is%20a%20ribonucleoprotein%20complex%2C,cause%20a%20range%20of%20genetic')
2. AnnotationURLCitation(end_index=722, start_index=515, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=Mammalian%20telomeres%20are%20repetitive%20sequences,somatic%20cells%20from%20indefinite%20replication')
3. AnnotationURLCitation(end_index=1077, start_index=913, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=responses,somatic%20cells%20from%20indefinite%20replication')
4. AnnotationURLCitation(end_index=1405, start_index=1208, title='Telomerase - Polymerases - Transferases - Enzymes - Products', type='url_citation', url='https://www.axonmedchem.com/products/enzymes/transferases/polymerases/telomerase#:~:text=the%20solution%20of%20both%20chromosome,continuously%20dividing%20cells%20such%20as')
5. AnnotationURLCitation(end_index=1711, start_index=1568, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=Telomerase%20is%20an%20enzyme%20that,2')
6. AnnotationURLCitation(end_index=1998, start_index=1854, title='Telomerase', type='url_citation', url='https://en.wikipedia.org/wiki/Telomerase#:~:text=Telomerase%20is%20a%20reverse%20transcriptase,absent%20in%20most%20%2019s')
7. AnnotationURLCitation(end_index=2230, start_index=2124, title='Telomerase', type='url_citation', url='https://en.wikipedia.org/wiki/Telomerase#:~:text=By%20using%20TERC%2C%20TERT%20can,5')
8. AnnotationURLCitation(end_index=2604, start_index=2410, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=When%20telomeres%20reach%20a%20critical,somatic%20cells%20from%20indefinite%20replication')
9. AnnotationURLCitation(end_index=2801, start_index=2605, title='Telomerase - Polymerases - Transferases - Enzymes - Products', type='url_citation', url='https://www.axonmedchem.com/products/enzymes/transferases/polymerases/telomerase#:~:text=the%20solution%20of%20both%20chromosome,as%20those%20of%20unicellular%20eukaryotes')
10. AnnotationURLCitation(end_index=3257, start_index=3117, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=RNA%20,we%20discuss%20the%20transcriptional%20regulation')
11. AnnotationURLCitation(end_index=3471, start_index=3258, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=tumor%E2%80%91preventing%20mechanism%20in%20differentiated%20somatic,the%20evidence%20regarding%20the%20role')
12. AnnotationURLCitation(end_index=3893, start_index=3702, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=Telomerase%20is%20a%20ribonucleoprotein%20complex%2C,Conversely%2C%20germline%20mutations%20in%20telomerase')
13. AnnotationURLCitation(end_index=4081, start_index=3894, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=Telomerase%20is%20an%20enzyme%20that,restricted%20to%20germline%20and%20progenitor')
14. AnnotationURLCitation(end_index=4624, start_index=4444, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=complex%20formed%20by%20the%20RNA,24%20Cristofari%20and')
15. AnnotationURLCitation(end_index=5036, start_index=4872, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=shelterin%20,DNA%20damage%20can')
16. AnnotationURLCitation(end_index=5259, start_index=5037, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=%28Nguyen%2C%202021%3B%20Ghanim%20et%20al,advances%20in%20human%20telomerase%20structures')
17. AnnotationURLCitation(end_index=5681, start_index=5524, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=Telomeres%20comprise%20repetitive%20sequences%20at,6%2C2%7D.%20To%20serve')
18. AnnotationURLCitation(end_index=5970, start_index=5890, title='Telomerase', type='url_citation', url='https://en.wikipedia.org/wiki/Telomerase#:~:text=Mechanism')
19. AnnotationURLCitation(end_index=6407, start_index=6296, title='Telomerase', type='url_citation', url='https://en.wikipedia.org/wiki/Telomerase#:~:text=the%203%27%20strand%20of%20chromosomes,5')
20. AnnotationURLCitation(end_index=6929, start_index=6763, title='Structure of human telomerase holoenzyme with bound telomeric DNA | Nature', type='url_citation', url='https://www.nature.com/articles/s41586-021-03415-4#:~:text=Nature%20www.nature.com%20%20Subjects%20,In%20humans%2C%20telomerase%20is%20upregulated')
21. AnnotationURLCitation(end_index=7299, start_index=7133, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=et%20al,a%20key%20role%20in%20the')
22. AnnotationURLCitation(end_index=7486, start_index=7300, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=7BGB%29%20%28Zuo%20et%20al,related%20proteins%20could')
23. AnnotationURLCitation(end_index=7880, start_index=7658, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=%28Nguyen%2C%202021%3B%20Ghanim%20et%20al,advances%20in%20human%20telomerase%20structures')
24. AnnotationURLCitation(end_index=8067, start_index=7881, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=7BGB%29%20%28Zuo%20et%20al,related%20proteins%20could')
25. AnnotationURLCitation(end_index=8571, start_index=8447, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=also%20the%20rate,2')
26. AnnotationURLCitation(end_index=8894, start_index=8700, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=When%20telomeres%20reach%20a%20critical,somatic%20cells%20from%20indefinite%20replication')
27. AnnotationURLCitation(end_index=9276, start_index=9152, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=also%20the%20rate,2')
28. AnnotationURLCitation(end_index=9458, start_index=9277, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=deficiency%20%2842%29,rapid%20TERT%20activation%20in%20both')
29. AnnotationURLCitation(end_index=9802, start_index=9638, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=responses,somatic%20cells%20from%20indefinite%20replication')
30. AnnotationURLCitation(end_index=10004, start_index=9803, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=Telomeres%20are%20critical%20contributors%20to,involve%20hTERT%20promoter%20mutations%2C%20hTERT')
31. AnnotationURLCitation(end_index=10419, start_index=10217, title='Telomere function and regulation from mouse models to human ageing and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-024-00800-5#:~:text=Telomeres%20protect%20the%20ends%20of,disorders%20include%20dyskeratosis%20congenita%2C%20H%C3%B8yeraal%E2%80%93Hreidarsson')
32. AnnotationURLCitation(end_index=10577, start_index=10420, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=Telomeres%20comprise%20repetitive%20sequences%20at,6%2C2%7D.%20To%20serve')
33. AnnotationURLCitation(end_index=11220, start_index=11077, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=Telomerase%20is%20an%20enzyme%20that,2')
34. AnnotationURLCitation(end_index=11409, start_index=11221, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=contributes%20to%20the%20maintenance%20of,24%20Cristofari%20and')
35. AnnotationURLCitation(end_index=11599, start_index=11475, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=also%20the%20rate,2')
36. AnnotationURLCitation(end_index=12070, start_index=11889, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=deficiency%20%2842%29,rapid%20TERT%20activation%20in%20both')
37. AnnotationURLCitation(end_index=12268, start_index=12071, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=CD8%2B%20and%20CD4%2B%20T%20cells,of%20TERT%20expression%20and%20telomerase')
38. AnnotationURLCitation(end_index=12833, start_index=12680, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=and%20we%20have%20recently%20begun,relevance%20of%20each%20of%20these')
39. AnnotationURLCitation(end_index=13119, start_index=12992, title='Telomere function and regulation from mouse models to human ageing and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-024-00800-5#:~:text=syndrome%2C%20Coats%20plus%20syndrome%20and,like')
40. AnnotationURLCitation(end_index=13726, start_index=13563, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=and%20we%20have%20recently%20begun,these%20steps%20of%20telomerase%20biogenesis')
41. AnnotationURLCitation(end_index=14194, start_index=14041, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=and%20we%20have%20recently%20begun,relevance%20of%20each%20of%20these')
42. AnnotationURLCitation(end_index=14926, start_index=14767, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=Increased%20levels%20of%20telomerase%20are,cause%20a%20range%20of%20genetic')
43. AnnotationURLCitation(end_index=15140, start_index=14927, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=tumor%E2%80%91preventing%20mechanism%20in%20differentiated%20somatic,the%20evidence%20regarding%20the%20role')
44. AnnotationURLCitation(end_index=15551, start_index=15338, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=tumor%E2%80%91preventing%20mechanism%20in%20differentiated%20somatic,the%20evidence%20regarding%20the%20role')
45. AnnotationURLCitation(end_index=15890, start_index=15731, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=Increased%20levels%20of%20telomerase%20are,cause%20a%20range%20of%20genetic')
46. AnnotationURLCitation(end_index=16098, start_index=15891, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=frequencies%20in%20numerous%20cancer%20types,as%20squamous%20cell%20carcinoma%20of')
47. AnnotationURLCitation(end_index=16591, start_index=16417, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=Activating%20mutations%20in%20the%20proximal,2018')
48. AnnotationURLCitation(end_index=17054, start_index=16851, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=Somatic%20mutations%20in%20the%20TERT,have%20contributed%20to%20define%20their')
49. AnnotationURLCitation(end_index=17249, start_index=17055, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=rate%20of%20mutations%20have%20been,and%20late%20events%20in%20others')
50. AnnotationURLCitation(end_index=17554, start_index=17381, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=diverse%20cancer%20types%20,Hockemeyer%2C%202020')
51. AnnotationURLCitation(end_index=17771, start_index=17555, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=In%20glioblastoma%2C%20TERT%20promoter%20mutations,driver%20mutations%20in%20cancer%20cells')
52. AnnotationURLCitation(end_index=18266, start_index=18059, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=Telomerase%20activity%20is%20upregulated%20in,by%20high%20levels%20of%20telomerase')
53. AnnotationURLCitation(end_index=18415, start_index=18267, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=al,1%29%20Tax%20protein')
54. AnnotationURLCitation(end_index=18804, start_index=18617, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=sustain%20cell%20transformation%2C%20are%20characterized,2022a')
55. AnnotationURLCitation(end_index=19139, start_index=18961, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=phenotypes%20%281%29,or%2C%20less%20frequently%2C%20through%20alternative')
56. AnnotationURLCitation(end_index=19639, start_index=19461, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=phenotypes%20%281%29,or%2C%20less%20frequently%2C%20through%20alternative')
57. AnnotationURLCitation(end_index=20103, start_index=19884, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=Cancer%20cells%20acquire%20replicative%20immortality,well%20as%20the%20reverse%20transcriptase')
58. AnnotationURLCitation(end_index=20284, start_index=20104, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=complex%20formed%20by%20the%20RNA,24%20Cristofari%20and')
59. AnnotationURLCitation(end_index=20804, start_index=20627, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=The%20hTERT%20gene%20is%20located,E2F%2C%20while%20the%20positive%20ones')
60. AnnotationURLCitation(end_index=21099, start_index=20954, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=however%2C%20located%20at%20the%20181,23')
61. AnnotationURLCitation(end_index=21464, start_index=21257, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=Telomerase%20activity%20is%20upregulated%20in,by%20high%20levels%20of%20telomerase')
62. AnnotationURLCitation(end_index=21613, start_index=21465, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=al,1%29%20Tax%20protein')
63. AnnotationURLCitation(end_index=21902, start_index=21757, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=however%2C%20located%20at%20the%20181,23')
64. AnnotationURLCitation(end_index=22107, start_index=21903, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=tightly%20controlled%20by%20several%20regulatory,However%2C%20most%20of%20these')
65. AnnotationURLCitation(end_index=22405, start_index=22260, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=however%2C%20located%20at%20the%20181,23')
66. AnnotationURLCitation(end_index=23077, start_index=22883, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=of%20telomerase%20expression,showed%20that%20the%20telomeric%20factor')
67. AnnotationURLCitation(end_index=23284, start_index=23078, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=promoter%20sequences%20%28Mukherjee%20et%20al,in%20the%20TERT%20promoter%20region')
68. AnnotationURLCitation(end_index=24023, start_index=23859, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=shelterin%20,DNA%20damage%20can')
69. AnnotationURLCitation(end_index=24204, start_index=24024, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=complex%20formed%20by%20the%20RNA,24%20Cristofari%20and')
70. AnnotationURLCitation(end_index=24512, start_index=24348, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=shelterin%20,DNA%20damage%20can')
71. AnnotationURLCitation(end_index=24735, start_index=24513, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=%28Nguyen%2C%202021%3B%20Ghanim%20et%20al,advances%20in%20human%20telomerase%20structures')
72. AnnotationURLCitation(end_index=25269, start_index=25189, title='Telomerase', type='url_citation', url='https://en.wikipedia.org/wiki/Telomerase#:~:text=Mechanism')
73. AnnotationURLCitation(end_index=25513, start_index=25433, title='Telomerase', type='url_citation', url='https://en.wikipedia.org/wiki/Telomerase#:~:text=Mechanism')
74. AnnotationURLCitation(end_index=25668, start_index=25514, title='Telomerase', type='url_citation', url='https://en.wikipedia.org/wiki/Telomerase#:~:text=Telomerase%20can%20bind%20the%20first,Telomerase%20reverses%20telomere%20shortening')
75. AnnotationURLCitation(end_index=25973, start_index=25804, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=contributes%20to%20the%20maintenance%20of,24')
76. AnnotationURLCitation(end_index=26517, start_index=26329, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=Finally%2C%20although%20hTERT%20is%20the,of%20hTERT%20expression%2C%20the%20results')
77. AnnotationURLCitation(end_index=27300, start_index=27089, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=match%20at%20L164%20expression%20%2830%29,protection%2C%20potentially%20aiding%20in%20the')
78. AnnotationURLCitation(end_index=27487, start_index=27301, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=oxidative%20stress%20%2825%29,and%20has%20been%20implicated%20in')
79. AnnotationURLCitation(end_index=27877, start_index=27686, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=expression%20%2830%29,protection%2C%20potentially%20aiding%20in%20the')
80. AnnotationURLCitation(end_index=28374, start_index=28237, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=34%29,Once%20in')
81. AnnotationURLCitation(end_index=28596, start_index=28375, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=the%20nucleus%2C%20TERT%20binds%20to,catenin%20transcriptional%20complex%2C%20thereby%20influencing')
82. AnnotationURLCitation(end_index=28949, start_index=28812, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=34%29,Once%20in')
83. AnnotationURLCitation(end_index=29149, start_index=28950, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=including%20IL,catenin%20transcriptional%20complex%2C%20thereby%20influencing')
84. AnnotationURLCitation(end_index=29666, start_index=29445, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=the%20nucleus%2C%20TERT%20binds%20to,catenin%20transcriptional%20complex%2C%20thereby%20influencing')
85. AnnotationURLCitation(end_index=30073, start_index=29916, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=match%20at%20L174%2034%29,Once%20in')
86. AnnotationURLCitation(end_index=30274, start_index=30074, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=pathway%2C%20in%20which%20TERT%20is,critical%20role%20in%20regulating%20immune')
87. AnnotationURLCitation(end_index=30966, start_index=30736, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=Beyond%20its%20canonical%20role%2C%20TERT%2Ftelomerase,preservation%20of%20mitochondrial%20integrity%20under')
88. AnnotationURLCitation(end_index=31164, start_index=30967, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=There%20is%20substantial%20evidence%20supporting,altering%20factors%20%2833')
89. AnnotationURLCitation(end_index=31928, start_index=31742, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=7BGB%29%20%28Zuo%20et%20al,related%20proteins%20could')
90. AnnotationURLCitation(end_index=32095, start_index=31929, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=et%20al,a%20key%20role%20in%20the')
91. AnnotationURLCitation(end_index=32503, start_index=32382, title='Cryo-EM structure of human telomerase dimer reveals H/ACA RNP-mediated dimerization - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7618144/#:~:text=Skip%20to%20main%20content%20Science,')
92. AnnotationURLCitation(end_index=32911, start_index=32725, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=7BGB%29%20%28Zuo%20et%20al,related%20proteins%20could')
93. AnnotationURLCitation(end_index=33078, start_index=32912, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=et%20al,a%20key%20role%20in%20the')
94. AnnotationURLCitation(end_index=33598, start_index=33412, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=7BGB%29%20%28Zuo%20et%20al,related%20proteins%20could')
95. AnnotationURLCitation(end_index=33812, start_index=33599, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=match%20at%20L616%20advanced%20stages,also%20been%20identified%20as%20telomerase')
96. AnnotationURLCitation(end_index=34139, start_index=33958, title='Telomerase structural biology comes of age - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36081246/#:~:text=Telomerase%20structural%20biology%20comes%20of,in%20biogenesis%2C%20assembly%2C%20localization%2C%20or')
97. AnnotationURLCitation(end_index=34585, start_index=34479, title='Recent advancements in the structural biology of human telomerase and their implications for improved design of cancer therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9984990/#:~:text=PMC%20pmc,%E2%9C%89%7D')
98. AnnotationURLCitation(end_index=35127, start_index=34946, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=deficiency%20%2842%29,rapid%20TERT%20activation%20in%20both')
99. AnnotationURLCitation(end_index=35325, start_index=35128, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=CD8%2B%20and%20CD4%2B%20T%20cells,of%20TERT%20expression%20and%20telomerase')
100. AnnotationURLCitation(end_index=35788, start_index=35569, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=telomerase%20activity%2C%20tightly%20regulated%20throughout,rapid%20TERT%20activation%20in%20both')
101. AnnotationURLCitation(end_index=35948, start_index=35789, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=match%20at%20L223%20persistent%20T,46')
102. AnnotationURLCitation(end_index=36343, start_index=36114, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=match%20at%20L64%20mechanisms%20involving,immunosenescence%20by%20augmenting%20TERT%2Ftelomerase%20activity')
103. AnnotationURLCitation(end_index=36514, start_index=36344, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=2%20Canonical%20and%20non,of%20TERT%2Ftelomerase')
104. AnnotationURLCitation(end_index=37189, start_index=37052, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=34%29,Once%20in')
105. AnnotationURLCitation(end_index=37411, start_index=37190, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=the%20nucleus%2C%20TERT%20binds%20to,catenin%20transcriptional%20complex%2C%20thereby%20influencing')
106. AnnotationURLCitation(end_index=38842, start_index=38639, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=Somatic%20mutations%20in%20the%20TERT,have%20contributed%20to%20define%20their')
107. AnnotationURLCitation(end_index=39364, start_index=39164, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=regulators%20from%20DNA%20G,in%20cancer%20development%2C%20their%20clinical')
108. AnnotationURLCitation(end_index=39580, start_index=39365, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=Furthermore%2C%20TERT%20promoter%20mutations%20cooperate,a%20major%20indicator%20of%20poor')
109. AnnotationURLCitation(end_index=40129, start_index=39951, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=%28%E2%89%A515,in%20some%20tumour%20types%20including')
110. AnnotationURLCitation(end_index=40337, start_index=40130, title='Frontiers | Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations', type='url_citation', url='https://www.frontiersin.org/journals/plant-science/articles/10.3389/fcell.2023.1286683/full#:~:text=frequencies%20in%20numerous%20cancer%20types,as%20squamous%20cell%20carcinoma%20of')
111. AnnotationURLCitation(end_index=42086, start_index=41853, title="Geron's blood disorder drug gets FDA advisers' backing", type='url_citation', url='https://www.reuters.com/business/healthcare-pharmaceuticals/gerons-blood-disorder-drug-gets-fda-advisers-backing-2024-03-14/#:~:text=FDA%20advisers%20have%20expressed%20support,drug%20and%20would%20compete%20with')
112. AnnotationURLCitation(end_index=42660, start_index=42429, title="Geron's blood disorder drug gets FDA advisers' backing", type='url_citation', url='https://www.reuters.com/business/healthcare-pharmaceuticals/gerons-blood-disorder-drug-gets-fda-advisers-backing-2024-03-14/#:~:text=FDA%20advisers%20have%20expressed%20support,FDA%20approval%20for%20the%20same')
113. AnnotationURLCitation(end_index=43313, start_index=43141, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=against%20Non,dG.%20The%20first%20trial')
114. AnnotationURLCitation(end_index=43519, start_index=43314, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=immunotherapy%20against%20advanced%20tumors%20,dG.%20The%20first%20trial')
115. AnnotationURLCitation(end_index=44040, start_index=43854, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=7BGB%29%20%28Zuo%20et%20al,related%20proteins%20could')
116. AnnotationURLCitation(end_index=44231, start_index=44041, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=match%20at%20L552%207BGB%29%20,related%20proteins%20could')
117. AnnotationURLCitation(end_index=44915, start_index=44701, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=Given%20its%20role%20in%20tumorigenesis%2C,A%20similar%20approach%20showed%20that')
118. AnnotationURLCitation(end_index=45732, start_index=45519, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=match%20at%20L616%20advanced%20stages,also%20been%20identified%20as%20telomerase')
119. AnnotationURLCitation(end_index=46742, start_index=46589, title='Human TERT promoter mutations as a prognostic biomarker in glioma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7954705/#:~:text=Human%20TERT%20promoter%20mutations%20as,DNA%20methylation%20of%20the')
120. AnnotationURLCitation(end_index=48644, start_index=48533, title='2025-05-25 | Cycloastragenol', type='url_citation', url='https://en.wikipedia.org/wiki/Cycloastragenol#:~:text=2025,CD8%20T%20cells%20found%20that')
121. AnnotationURLCitation(end_index=49648, start_index=49509, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=1%C2%A0%20%20,49%3A349%E2%80%93357')
122. AnnotationURLCitation(end_index=49983, start_index=49844, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=1%C2%A0%20%20,49%3A349%E2%80%93357')
123. AnnotationURLCitation(end_index=50127, start_index=49984, title='Molecular and Clinical Oncology', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mco.2023.2657#:~:text=compared%20to%20healthy%20tissues%20,3')
124. AnnotationURLCitation(end_index=51390, start_index=51250, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=RNA%20,we%20discuss%20the%20transcriptional%20regulation')
125. AnnotationURLCitation(end_index=51550, start_index=51391, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=Increased%20levels%20of%20telomerase%20are,cause%20a%20range%20of%20genetic')
126. AnnotationURLCitation(end_index=51987, start_index=51771, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=likely%20to%20adopt%20telomerase,for%20more%20personalized%20treatment%20strategies')
127. AnnotationURLCitation(end_index=52193, start_index=51988, title='Frontiers | Recent progress in human telomerase structure and its therapeutic targeting', type='url_citation', url='https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1681988/full#:~:text=immunotherapy%20against%20advanced%20tumors%20,dG.%20The%20first%20trial')
128. AnnotationURLCitation(end_index=53376, start_index=53154, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=replicative%20and%20premature%20senescence,encapsulates%20recent%20advancements%20in%20understanding')
129. AnnotationURLCitation(end_index=53606, start_index=53377, title='Frontiers | Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1465006/full#:~:text=match%20at%20L64%20mechanisms%20involving,immunosenescence%20by%20augmenting%20TERT%2Ftelomerase%20activity')
130. AnnotationURLCitation(end_index=54336, start_index=54199, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=RNA%20,the%20telomerase%20complex%2C%20the%20cellular')
131. AnnotationURLCitation(end_index=54500, start_index=54337, title='Regulation of human telomerase in homeostasis and disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7377944/#:~:text=and%20we%20have%20recently%20begun,these%20steps%20of%20telomerase%20biogenesis')

Telomerase Reverse Transcriptase (TERT): Structure, Function, Regulation, and Biological Significance

Summary

Telomerase reverse transcriptase (TERT) is the catalytic protein subunit of telomerase, a specialized ribonucleoprotein enzyme responsible for synthesizing and maintaining telomeric DNA sequences at chromosomal ends[1][11]. TERT catalyzes the template-directed addition of TTAGGG repeats to the 3′ overhang of telomeres through reverse transcriptase activity, utilizing an intrinsic RNA component as its template[1][2]. Beyond its canonical role in telomere maintenance, TERT exhibits non-canonical functions including mitochondrial DNA protection, regulation of oxidative stress, and modulation of gene expression independent of telomere synthesis[15][18]. TERT expression is tightly regulated at transcriptional and post-translational levels, with dysregulation implicated in both cellular senescence and cancer development[16][38]. This comprehensive analysis examines TERT's catalytic mechanism, structural organization, regulation, cellular localization, and diverse biological functions based on current molecular and structural evidence.

The Enzymatic Core: Primary Function and Catalytic Mechanism

Fundamental Role in Telomeric DNA Synthesis

TERT functions as a specialized reverse transcriptase that catalyzes the synthesis of telomeric DNA repeats onto the three-prime ends of linear eukaryotic chromosomes.[1][2] The enzyme differs fundamentally from conventional reverse transcriptases in that it uses an intrinsic RNA template contained within the telomerase complex itself, rather than relying on an external RNA template such as those found in retroviral systems[2][8]. The core catalytic reaction performed by TERT involves the step-wise addition of nucleotides in the TTAGGG sequence, characteristic of mammalian telomeres, to the chromosome terminus[1]. This process occurs through RNA-dependent DNA polymerization, where TERT's active site catalyzes nucleotide addition using deoxyribonucleotides (dGTP, dTTP, dATP, dCTP) while base-pairing the growing DNA product against the RNA template sequence contained within the telomerase RNA component (TERC)[2][8].

The catalytic mechanism employed by TERT involves a two-metal-ion catalytic mechanism analogous to other polymerases, with three invariant aspartic acid residues within the active site that participate directly in nucleotide addition[7][50]. These catalytic residues, located within conserved reverse transcriptase (RT) motifs A and C, coordinate metal ions that facilitate phosphodiester bond formation during DNA synthesis[7]. The geometry of TERT's active site differs substantially from conventional reverse transcriptases, as it must accommodate not only the growing RNA-DNA duplex but also the translocating template during processive repeat addition[8][50]. Importantly, the active site structure and positioning within TERT create a ring-like configuration rather than the horseshoe shape typical of conventional reverse transcriptases, reflecting the unique structural requirements for telomerase function[8].

Template-Directed Synthesis and Sequence Fidelity

The template for telomeric repeat synthesis is defined by a conserved sequence region within the telomerase RNA component, and TERT must recognize and precisely use only this defined sequence region, preventing erroneous copying of adjacent RNA sequences.[8][17][33] The fidelity of TERT's template copying represents a critical regulatory feature of telomerase, as incorrect incorporation of non-telomeric sequences would produce defective chromosome ends incapable of proper telomere capping and protection[17]. Recent structural and biochemical evidence reveals that TERT achieves this specificity through multiple mechanisms, including the physical definition of template boundaries by RNA secondary structures and the conformational properties of TERT's active site that restrict access to only the designated template region[17][33].

The template boundary definition in human telomerase depends critically on the helix P1b structure in the telomerase RNA, which maintains an appropriate linker distance between a conserved anchoring element and the template proper[33]. Disruption of this structural element in the RNA leads to TERT reading through the normal template boundary and incorporating non-telomeric sequences into the DNA product, resulting in aberrant telomeric DNA[33]. This finding demonstrates that TERT's fidelity depends not solely on properties intrinsic to the protein itself, but rather on coordinated interactions between TERT and specific structural elements within the telomerase RNA partner. Additionally, TERT contains a conserved motif designated motif 3, located between conserved RT motifs 2 and A, that appears to regulate species-specific aspects of telomerase biochemistry including repeat addition processivity, suggesting that this telomerase-specific sequence element serves regulatory rather than purely catalytic functions[7][50].

Repeat Addition Processivity: Multiple Round Synthesis

TERT exhibits the unique capability to catalyze multiple sequential rounds of telomeric DNA repeat synthesis while remaining bound to a single DNA primer, a property termed repeat addition processivity (RAP), which is essential for efficient telomere elongation in vivo.[7][8][14] This processivity distinguishes telomerase from conventional DNA polymerases and reflects the specialized catalytic cycle performed by TERT. Following synthesis of a complete six-nucleotide telomeric repeat (GGTTAG in vertebrates), TERT must catalyze dissociation of the nascent RNA-DNA product-template duplex, reposition the DNA 3′ end to re-anneal with the 5′ region of the template, and re-engage the active site for synthesis of the next repeat[8][14][51]. The ability to perform this cycle repeatedly without complete dissociation from the DNA primer depends on TERT-specific structural features and interactions with accessory proteins such as the POT1-TPP1 complex[8][26][51].

Recent single-molecule studies employing Förster resonance energy transfer (FRET) have illuminated the kinetic details of repeat addition processivity[54]. These studies reveal that following completion of a single telomeric repeat, the 3′ end of the DNA product dynamically samples multiple base-pairing registers along the downstream template region, establishing an equilibrium wherein repositioning occurs transiently[54]. The rate-limiting step for repeat addition processivity appears to be a conformational rearrangement of the RNA-DNA duplex within the TERT active site following template realignment, rather than the primary process of template realignment itself[54]. Additionally, the binding affinity of TERT's active site for the realigned RNA-DNA hybrid directly determines repeat-addition processivity efficiency, with increased binding affinity correlating with enhanced processivity in TERT mutant studies[51]. This mechanistic insight demonstrates that TERT's ability to perform multiple rounds of repeat synthesis is fundamentally limited by the strength of its interaction with the repositioned template-primer duplex.

Structural Organization and Domains

Quaternary Architecture and Domain Composition

TERT contains 1132 amino acids organized into four conserved functional domains: the telomerase essential N-terminal (TEN) domain, the telomerase RNA-binding domain (TRBD), the central reverse transcriptase (RT) domain, and the C-terminal extension (CTE).[1][10][20] Each of these domains contributes distinct structural and functional properties essential for telomerase activity. The modular organization of TERT allows for differential regulation of its various functions and for interactions with distinct binding partners that facilitate telomerase assembly and recruitment to telomeres[20][50].

The N-terminal TEN domain, encompassing the most amino-proximal region of TERT, exhibits binding affinity for single-stranded telomeric DNA and contains residues essential for telomerase activity[7][50]. This domain displays a novel protein fold distinct from other known nucleic acid-binding domains, suggesting TERT-specific evolutionary adaptations for telomeric DNA recognition[7]. The TEN domain also provides binding sites for the shelterin complex protein TPP1, which facilitates telomerase recruitment to telomeres and enhances catalytic processivity[10][24][26]. Interestingly, TERT from certain organisms lacks a TEN domain entirely, and Saccharomyces cerevisiae telomerase can function without this domain in vivo, suggesting that while the TEN domain enhances efficiency, it is not absolutely obligatory for catalytic function[8]. However, the TEN domain does contribute critical anchoring interactions that stabilize DNA binding during repeat synthesis and enables repeat addition processivity through specific interactions with DNA substrates[8][50].

The telomerase RNA-binding domain (TRBD) represents another unique structural element of TERT with no clear homology to RNA-binding domains in other proteins[7][20]. The TRBD comprises helical motifs including the CP, QFP, and T motifs that mediate high-affinity binding to the three-way junction domain of the telomerase RNA component[7][20]. This domain is essential for telomerase assembly, as it directly contacts the CR4/5 domain of telomerase RNA (also called the three-way junction), with this TRBD-CR4/5 interaction being much stronger than the interaction between the RT domain and the pseudoknot region of the RNA[8][20]. The structural specificity of TRBD-RNA interactions underscores the evolutionarily conserved nature of telomerase assembly requirements across diverse eukaryotic organisms.

The Reverse Transcriptase Domain and Catalytic Architecture

The central RT domain of TERT contains the catalytic center where nucleotide addition occurs and comprises multiple conserved reverse transcriptase motifs including motifs A, B, C, D, and 1-3, organized into fingers and palm subdomains analogous to other polymerases but with telomerase-specific modifications.[7][50] The RT domain exhibits conservation of the three-metal-ion catalytic mechanism fundamental to all reverse transcriptases, with aspartic acid residues at positions corresponding to those in HIV RT and other retroviral RTs[7][50]. However, the TERT RT domain contains a sizable insertion within the fingers subdomain between conserved motifs A and B′, termed the insertion in fingers domain (IFD), which distinguishes TERT from conventional reverse transcriptases[7][50]. This IFD insertion contains telomerase-specific residues required for normal telomere maintenance in vivo, with mutations in this region producing primer-specific defects in telomerase activity and altered repeat addition processivity[34].

The substrate-binding pocket of TERT's RT domain accommodates the RNA-DNA duplex formed between the incoming DNA product and the RNA template[8][50]. The fingers subdomain provides critical contacts with the RNA template backbone to position the template in the active site for nucleotide addition, while the palm subdomain contributes motifs that contact the growing DNA strand[10]. Notably, TERT's RT domain contains a unique motif designated motif 3, which shows evolutionary conservation in its predicted secondary structure but exhibits sequence variation restricted to vertebrate and ciliate telomerases[7][50]. Functional studies of motif 3 reveal that alterations in this region selectively affect repeat addition processivity both in vitro and in vivo, suggesting that motif 3 may specifically regulate the processivity features of telomerase catalysis[7].

The C-Terminal Extension and Its Functional Roles

The C-terminal extension (CTE) of TERT represents the thumblike domain characteristic of reverse transcriptases but exhibits only weak sequence conservation across species, suggesting it may harbor species-specific regulatory functions.[7][13][20][50] Despite this weak conservation, the CTE is essential for TERT catalytic function, with truncations of this region abolishing telomerase activity in vitro[13]. The CTE contributes to telomerase-specific functions including repeat addition processivity and telomere length maintenance in vivo[13]. Several regions within the CTE have been identified as critical for processivity through comprehensive mutational analysis, indicating that the CTE participates in substrate binding and positioning during repeat synthesis[13].

The CTE also contains structural elements that undergo conformational changes during the telomerase catalytic cycle[19]. Recent cryo-electron microscopy structures reveal that the CTE, together with the TRBD, forms a ring-like structure with the RT domain, creating a large cavity at the center that accommodates the RNA-DNA duplex during catalysis[8][50]. This ring-like architecture differs fundamentally from the horseshoe configuration of conventional reverse transcriptases and reflects TERT's specialized evolution for template-directed repeat synthesis[8]. Additionally, the CTE contains regions involved in binding accessory proteins and regulatory factors, including the 14-3-3 protein binding site at the C-terminus of hTERT, which regulates nuclear localization[9][13]. The conformational flexibility of the CTE appears to be important for function, as certain mutations that constrain the CTE reduce processivity while mutations that enhance conformational dynamics can increase repeat addition processivity[19].

Transcriptional Regulation of the TERT Gene

Promoter Structure and Transcriptional Control

The human TERT gene consists of 16 exons and 15 introns spanning approximately 35 kilobases, with the core promoter encompassing 330 base pairs upstream of the translation initiation codon plus 37 base pairs of exon 2, and this promoter region is GC-rich but lacks canonical TATA and CAAT boxes.[5][11] The TERT promoter architecture reflects a complex regulatory region controlled by multiple transcription factors, with the GC-rich sequence providing numerous binding sites for regulatory proteins in diverse cellular contexts[5][11][60]. The lack of TATA and CAAT boxes suggests that TERT transcription initiation involves non-canonical promoter recognition mechanisms, likely requiring specific combinations of transcription factors to establish productive transcription initiation[5].

Sequence analysis reveals that the TERT promoter contains two canonical E-box consensus sequences (5′-CACGTG-3′) at positions approximately −165 and +44 from the transcription start site, which serve as binding sites for E-box binding proteins including the MYC/MAX/MAD family of transcription factors[57][60]. Additionally, multiple GC-rich motifs within the TERT promoter constitute binding sites for the Sp1 transcription factor[57][60]. The abundance of transcription factor binding sites in the TERT promoter indicates that its expression is subject to multiple levels of control and can be regulated by different factors in different cellular contexts[5]. Importantly, the TERT promoter remains unmethylated in normal cells, whereas it becomes hypermethylated in cancer cells, representing an epigenetic modification that influences transcription factor accessibility[16][38][60].

Role of the MYC Transcription Factor Family

MYC represents a primary transcriptional activator of TERT that directly binds to E-box elements in the TERT core promoter in association with MAX, and MYC/MAX heterodimers activate TERT transcription by inducing topological DNA changes that facilitate transcription initiation.[16][57][60] The importance of MYC in TERT regulation is underscored by the observation that ectopic expression of c-MYC in human fibroblasts or epithelial cells robustly induces both TERT mRNA and telomerase activity[57][60]. In leukemic HL60 cells, high c-MYC expression correlates with MYC/MAX binding to TERT promoter E-boxes and elevated TERT mRNA abundance, whereas upon terminal differentiation of these cells, c-MYC expression diminishes and MAD1 expression increases, with MAD1 subsequently replacing MYC on the TERT promoter and repressing transcription[57][60].

Structural studies using atomic force microscopy reveal that MYC/MAX dimers bind with equal specificity to both E-box sequences in the TERT promoter, suggesting that both sites may be occupied simultaneously to achieve maximal transcriptional activation[57]. Furthermore, MYC functions as a downstream effector of several cellular signaling pathways that regulate proliferation and cell fate, indicating that TERT expression can be modulated through diverse cellular signals[57]. In addition to direct MYC binding to E-boxes, MYC cooperates with other transcription factors, particularly SP1, to achieve robust TERT activation, with transactivation studies showing that disruption of SP1 binding sites attenuates MYC/MAX-mediated TERT promoter activation[57][60]. This cooperative binding suggests an integrated regulatory model where MYC and SP1 simultaneously occupy the TERT promoter to recruit additional factors necessary for transcription initiation.

Interestingly, MYC can also function as a repressor of TERT transcription in certain cellular contexts, a property that appears to operate independently of E-box binding and reflects the context-dependent nature of MYC's transcriptional regulation[57]. The inhibition of MYC expression has been shown to increase TERT transcription in normal cells through a mechanism independent of E-boxes, resulting in increased active histone marks on the TERT promoter[57]. This apparent paradox may reflect MYC's role in coordinating diverse cellular programs, wherein MYC promotes proliferation through TERT activation in proliferating cells but simultaneously represses TERT through indirect mechanisms in cells undergoing differentiation or quiescence.

TERT Promoter Mutations in Cancer

Two highly prevalent somatic mutations in the TERT promoter, designated C228T and C250T (numbered relative to the start codon), occur in a significant proportion of human cancers and create novel binding sites for ETS family transcription factors, leading to increased TERT transcription and telomerase activation.[16][24][38][41] These mutations represent gain-of-function alterations that specifically activate TERT expression in cancer cells, with C228T mutations occurring in approximately 70% of melanomas and C250T mutations in approximately 20% of glioblastomas[38][41]. The cancer-associated mutations work by creating binding sites for GA-binding proteins (GABPA and GABPB1), members of the ETS family of transcription factors, which are not recognized by the wild-type TERT promoter[16][24][38].

Mechanistically, the TERT promoter mutations enable what has been termed "enhancer hijacking," wherein super-enhancer elements normally located distant from the TERT locus are brought into proximity with the mutant TERT transcription start site through rearrangement of chromatin structure[16][38]. This process disrupts the Polycomb-mediated silencing that normally keeps TERT repressed in differentiated somatic cells, allowing transcription factor recruitment and robust TERT expression[16][38]. The TERT promoter mutations demonstrate selective pressure during cancer evolution, appearing with higher frequency in cancers arising from tissues with low baseline telomerase expression and replicative capacity, likely because these cells require overcoming telomere shortening-imposed proliferative barriers[24][38].

Additional variants of TERT promoter mutations have been identified beyond the classic C228T and C250T mutations, including CC>TT tandem mutations at positions −124/−125 and −138/−139, which also generate ETS transcription factor binding sites[16][38]. In certain cancer types, mutations affecting MYC binding sites in the TERT promoter have been documented, suggesting that cancer cells employ multiple distinct mutational strategies to reactivate TERT expression[38][60]. Studies using genome editing to revert mutant TERT promoters to wild-type sequence show substantial reductions in endogenous telomerase activity and cancer cell proliferation, establishing a direct causal relationship between these mutations and cancer cell immortalization[38][41].

Epigenetic Regulation and Histone Modifications

TERT transcription is subject to regulation by histone acetylation and methylation, with increased histone acetylation and decreased repressive histone marks (particularly H3K27me3) correlating with TERT expression in telomerase-positive cells, while histone deacetylases can actively repress TERT transcription.[16][21][60] Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are recruited to the TERT promoter by transcription factors including MYC, MAX, MAD, and SP1, dependent on the promoter status and cellular context[16][60]. The demethylation of histones proximal to the TERT promoter, particularly removal of repressive marks like H3K27me3, mimics the low density of trimethylated histones seen in embryonic stem cells and allows recruitment of histone acetyltransferases that unwind chromatin and facilitate TERT transcription[1][16].

Recent evidence demonstrates that histone methyltransferases contribute to TERT regulation through specific modifications of histone H3. The protein SMYD3, functioning as a histone methyltransferase, directly binds to CCCTCC sequences in the TERT promoter and catalyzes H3-K4 tri-methylation, an active histone mark[60]. This SMYD3-mediated H3-K4 tri-methylation is required for optimal occupancy of c-MYC and SP1 on the TERT promoter, indicating that epigenetic factors cooperate intimately with sequence-specific transcription factors to regulate TERT[60]. The coordinated nature of these epigenetic modifications suggests that TERT transcription requires not only the presence of transcription factors but also active chromatin remodeling to achieve full promoter activity.

Oxygen levels represent an additional environmental parameter that influences TERT epigenetic regulation. During embryonic stem cell differentiation, lower oxygen conditions (physiological hypoxia, 2% oxygen) compared to ambient air conditions (21% oxygen) result in elevated TERT expression and telomerase activity, with this effect mediated by altered TERT promoter methylation patterns[21]. The role of DNA methyltransferase 3B (DNMT3B) appears critical in this oxygen-dependent regulation, as DNMT3B chemical inhibition reduces TERT promoter methylation and increases TERT expression during differentiation[21]. These findings reveal that TERT expression responds to developmental oxygen availability, suggesting that oxygen levels during tissue development may influence the balance between stem cell maintenance and differentiation through effects on telomerase expression.

Cellular Localization and Nuclear Import

Bipartite Nuclear Localization Signal and Importin-Mediated Import

TERT contains a bipartite nuclear localization signal (NLS) spanning amino acid residues 222 to 240 that is essential for efficient nuclear accumulation of the protein, with the NLS consisting of two clusters of basic amino acids (arginine and lysine residues) separated by an 11-amino acid spacer.[45] Mutations in either the first or second cluster of basic amino acids in the NLS dramatically reduce nuclear accumulation of TERT, with single-cluster mutations reducing nuclear localization to approximately 11% for first-cluster mutations and 3.7% for second-cluster mutations compared to wild-type TERT at 72.1% nuclear[45]. This bipartite NLS functions through the canonical Ran-importin system, wherein importin-α and importin-β proteins recognize the NLS and facilitate TERT transit through nuclear pore complexes in a Ran-GTP-dependent manner[45].

The identification of this bipartite NLS represents a previously uncharacterized pathway for ensuring proper cellular telomerase activity by facilitating nuclear import of TERT[45]. The dependence of this import on the Ran-importin system is demonstrated by experiments using dominant-negative Ran mutants, which inhibit NLS-mediated nuclear protein import and result in accumulation of TERT in the cytoplasm[45]. Additionally, the bipartite NLS sequence functions independently of the C-terminal nuclear export signal (NES), suggesting that nuclear import through the bipartite NLS and nuclear export through the NES motif represent distinct regulatory mechanisms that together determine TERT's subcellular localization[45].

Phosphorylation of Serine 227 and Akt-Mediated Nuclear Localization

Phosphorylation of serine 227 by the protein kinase Akt, which resides within the bipartite NLS region, is required for efficient nuclear translocation of TERT and represents a regulatory step coupling cell proliferation signals to telomerase activity.[45] Mutations of serine 227 to alanine substantially reduce the ability of TERT to accumulate in the nucleus, even when the bipartite NLS sequences themselves are intact[45]. This phosphorylation-dependent nuclear import mechanism links TERT localization to cell proliferation signaling, as Akt activity increases during growth factor stimulation and cell cycle entry[45]. The requirement for Akt-mediated phosphorylation of TERT at serine 227 for efficient nuclear localization suggests that cells regulate telomerase activity not only through transcriptional control of TERT expression but also through post-translational control of TERT nuclear localization.

Nuclear Export Signal and 14-3-3 Protein-Mediated Retention

TERT contains a leucine-rich nuclear export signal (NES) near its C-terminus that is recognized by the nuclear export receptor CRM1 (exportin-1), and this NES-mediated export is inhibited by binding of 14-3-3 family proteins, which enhance TERT nuclear accumulation.[9][45] The 14-3-3 family proteins bind to TERT via each protein's C-terminus, with this interaction required for efficient TERT nuclear accumulation[9]. The mechanism involves 14-3-3 proteins blocking the access of CRM1 to the TERT NES-like motif through physical occlusion, thereby preventing TERT nuclear export[9]. The 14-3-3 binding to TERT does not affect telomerase activity measured either in vitro or in cell extracts, indicating that 14-3-3 functions as a post-translational modifier controlling TERT intracellular localization rather than directly regulating catalytic activity[9].

The cytoplasmic or nuclear localization of TERT appears to be determined by the balance between NLS-mediated nuclear import and NES-mediated nuclear export that is modulated by 14-3-3 binding[9][45]. Under conditions that promote 14-3-3 binding or where CRM1-mediated export is inhibited by the drug leptomycin B, TERT accumulates in the nucleus[9][45]. This dual regulation through both nuclear import and nuclear export mechanisms provides cells with multiple points for controlling telomerase localization and activity in response to diverse cellular signals[9]. The ability of 14-3-3 proteins to modulate TERT nuclear accumulation by inhibiting NES-mediated export represents an elegant regulatory system wherein TERT protein modification influences its subcellular distribution without necessarily changing total cellular TERT levels.

SIRT1-Mediated Regulation of TERT Nuclear Localization

Recent evidence reveals that the NAD+-dependent deacetylase SIRT1 directly interacts with TERT and promotes TERT nuclear localization and protein stability.[3] The interaction between SIRT1 and TERT is mediated by the reverse transcriptase domain of TERT and the N-terminus of SIRT1, with this direct protein-protein interaction essential for efficient nuclear accumulation[3]. When TERT is co-expressed with intact SIRT1, the protein exhibits predominantly nuclear localization, whereas TERT co-expressed with N-terminal-deleted SIRT1 remains cytoplasmic[3]. The overexpression of SIRT1 enhances both the nuclear localization and protein stability of TERT, effects that occur similarly with both catalytically active SIRT1 and a deacetylase-inactive SIRT1 mutant[3], suggesting that the scaffolding role of SIRT1 protein-protein interactions rather than its catalytic deacetylase activity primarily drives TERT nuclear accumulation[3].

This SIRT1-TERT interaction represents a novel regulatory mechanism connecting cellular aging and metabolic status to telomerase function[3]. SIRT1 activity is sensitive to NAD+ levels, which fluctuate with cellular metabolic state and caloric availability, suggesting that TERT localization and thus telomerase activity may be responsive to metabolic signals through SIRT1-mediated regulation[3]. The findings implicate SIRT1 as a key regulator of TERT nucleocytoplasmic distribution and stability, providing mechanistic insights into aging-related changes in telomerase activity and their connection to metabolic regulation[3].

Post-Translational Modifications and Protein Interactions

Phosphorylation by Multiple Kinases

TERT undergoes phosphorylation at multiple sites by diverse kinases including protein kinase C (PKC), c-Abl tyrosine kinase, and BCR-ABL, with these modifications influencing telomerase holoenzyme assembly, nuclear localization, and catalytic activity.[10][24][39] Protein kinase C phosphorylation of TERT promotes the association between the chaperone heat shock protein 90 (Hsp90) and TERT, thereby maintaining telomerase holoenzyme integrity[39]. PKC activators such as phorbol myristate acetate enhance telomerase activity, whereas PKC inhibitors reduce it, demonstrating the functional importance of PKC-mediated phosphorylation for telomerase regulation[39]. In chronic myeloid leukemia cells expressing BCR-ABL, TERT expression and telomerase activity are elevated as a result of TERT phosphorylation at tyrosine residues by BCR-ABL, with the BCR-ABL inhibitor Gleevec reducing TERT phosphorylation and downregulating TERT mRNA[39].

Under conditions of genotoxic stress, c-Abl tyrosine kinase is activated by DNA damage and catalyzes tyrosine phosphorylation of TERT, which inhibits telomerase activity and negatively regulates telomere length[10][39]. This phosphorylation-mediated inhibition of telomerase by c-Abl represents a cell cycle checkpoint mechanism wherein DNA damage simultaneously activates p53-mediated apoptosis while simultaneously inhibiting telomerase to prevent unlimited cell division in damaged cells[10]. The specificity of different kinases for distinct TERT phosphorylation sites suggests that phosphorylation-mediated regulation provides a mechanism for integrating multiple cellular signals to modulate telomerase activity in response to diverse stimuli including growth factor signaling, metabolic state, and DNA damage.

Ubiquitination and Protein Stability

TERT undergoes ubiquitination by multiple ubiquitin ligases, with ubiquitin-mediated protein degradation representing an important mechanism for negative regulation of telomerase activity.[10][39] The Hsc70-interacting protein (CHIP), which functions as an E3 ubiquitin ligase and interacts with Hsc/Hsp70 chaperones, is physically associated with TERT and downregulates telomerase activity through ubiquitin-mediated proteasomal degradation[39]. The CHIP-mediated degradation of TERT results in cytoplasmic accumulation of TERT and reduced nuclear localization, suggesting that the ubiquitination occurs on cytoplasmic TERT and prevents its nuclear import[39]. Importantly, CHIP does not influence telomerase catalytic activity as measured in extract-based assays, indicating that CHIP's effects on telomerase activity are indirect and mediated through effects on TERT cellular localization and protein stability rather than direct inhibition of the catalytic domain[39].

The distinction between CHIP interaction and Hsp90 binding is functionally important, as CHIP appears to interact preferentially with intermediate or immature nonfunctional TERT species, whereas Hsp90 and its co-chaperone p23 interact with TERT to facilitate maturation into active telomerase[39][42]. This specificity suggests a quality control system wherein correctly folded and assembled TERT escapes degradation by CHIP and instead associates with Hsp90 for further maturation, while misfolded TERT is targeted for degradation[42]. Additional ubiquitin ligases including Makorin ring finger protein 1 have been identified as modulators of TERT stability in cancer, indicating that multiple ubiquitin ligases may cooperate or compete in regulating TERT levels under different cellular conditions.

Heat Shock Proteins and Telomerase Assembly

Heat shock proteins including HSP70 and HSP90, together with the co-chaperone p23 and AAA+ ATPases Pontin and Reptin, facilitate TERT proper folding, assembly with telomerase RNA, and maturation into catalytically active telomerase.[39][42] HSP70, a ubiquitous molecular chaperone that controls various cellular protein-folding and remodeling processes, transiently binds to TERT in the absence of telomerase RNA, suggesting a role in maintaining TERT in a conformation competent for RNA binding[10][39][42]. HSP90, accompanied by the co-chaperone p23, binds specifically with TERT and ensures its correct assembly with the template RNA, with HSP90 and p23 also loading TERT into Cajal bodies for generation of an enzymatically active telomerase complex[39][42]. Chemical inhibition of HSP90 reduces telomerase activity, indicating the functional importance of HSP90 in telomerase maturation[39][42].

The AAA+ ATPases Pontin and Reptin also associate with TERT, with knockdown of Pontin reducing telomerase activity as well as telomerase RNA levels[42]. In contrast to HSP90 and p23, which appear to associate with mature, enzymatically active telomerase, Reptin and Pontin seem to associate with a pool of hTERT not incorporated into enzymatically active telomerase, suggesting a potential role in telomerase assembly or remodeling of TERT conformations[42]. The requirement for multiple chaperone proteins in TERT maturation reflects the complexity of telomerase assembly and the need to properly position TERT's various domains to create a functional active site.

Subcellular Trafficking and Cajal Body Localization

Telomerase Localization to Cajal Bodies

TERT and telomerase RNA localize to Cajal bodies, nuclear organelles where various small nuclear RNAs and proteins undergo processing and assembly, with the telomerase Cajal body protein 1 (TCAB1) serving as the primary mediator of telomerase Cajal body localization.[20][42][49] The CAB-box motif present in the terminal hairpin of telomerase RNA serves as a recognition signal for TCAB1, with TCAB1 interaction with this motif essential for telomerase localization to Cajal bodies[42][49]. TCAB1, also known as WRAP53, constitutively resides in Cajal bodies and recruits telomerase by binding to the CAB-box sequence, thereby directing telomerase assembly to this specialized nuclear compartment[42][49]. The significance of Cajal body localization lies in the assembly of the telomerase holoenzyme from newly transcribed telomerase RNA components and the maturation of telomerase into its catalytically active form[42].

Interestingly, the requirement for Cajal bodies in telomerase assembly remains somewhat controversial, as coilin gene disruption does not affect telomerase function in telomere maintenance, yet coilin depletion can reduce endogenous hTERT and telomerase RNA recruitment to telomeres[42][49]. This apparent paradox may reflect functional redundancy in the nucleoplasm that partially compensates for loss of Cajal body-mediated telomerase assembly. The cell cycle regulation of telomerase localization reveals that telomerase accumulation in Cajal bodies peaks during S phase when telomere replication occurs[49], suggesting that telomerase availability for telomere elongation is temporally coordinated with DNA replication through cell cycle-dependent changes in telomerase-Cajal body association[49].

Cell Cycle Regulation of Telomerase Holoenzyme Assembly

Detailed analysis reveals that TCAB1 association with telomerase RNA undergoes cell cycle regulation, with TCAB1 dissociating from both telomerase RNA and from Cajal bodies during mitosis, then reassociating during G1 phase, indicating that telomerase holoenzyme assembly is dynamically regulated during the cell cycle.[49] The maximum interaction between TCAB1 and telomerase RNA occurs in G1 phase, with minimal association in mitotic cells[49]. This reversible disassembly of the active telomerase holoenzyme during mitosis and reassembly in G1 suggests that cells may limit telomerase availability for telomere elongation to specific phases of the cell cycle, potentially restricting telomere synthesis to early G1 when the replication machinery is being assembled[49]. The TCAB1-telomerase RNA interaction appears to be independent of TERT, as TERT is not required for TCAB1-hTR association[49], suggesting that TCAB1 binds telomerase RNA through interactions with the RNA structure itself rather than through TERT-mediated protein-protein bridges.

Notably, the irreversible assembly of hTERT with telomerase RNA appears to contrast with the reversible TCAB1 association, suggesting a model where TERT and RNA form a stable minimal catalytic core that persists throughout the cell cycle, while TCAB1 and other holoenzyme components are dynamically regulated in a cell cycle-dependent manner[49]. This temporal organization of telomerase assembly provides an additional regulatory layer beyond transcriptional and post-translational modification control, allowing cells to restrict active telomerase availability to appropriate phases of the cell cycle.

Interaction with the Shelterin Complex and Telomere Recruitment

TPP1 as the Primary Telomerase Recruitment Factor

The shelterin complex component TPP1 (telomeric repeat-binding factor 1-interacting nuclear protein 2) serves as the primary factor for telomerase recruitment to telomeres, mediating direct interaction with TERT's TEN domain.[10][24][26][39] TPP1 binds the TEN domain of TERT through its oligonucleotide/oligosaccharide-binding (OB) fold, with this interaction essential for telomerase recruitment to the single-stranded telomeric overhang[10][26][39]. The TPP1-TEN domain interaction creates a complex that positions telomerase appropriately for interaction with the 3′ telomeric overhang, initiating the primer-template interaction necessary for telomere elongation[10][24]. The specific residues within the TPP1 OB-fold critical for TERT binding have been identified through structural and mutational studies, revealing a dedicated binding pocket on TPP1 that accommodates the TEN domain[26].

Deletion of TPP1 elicits robust DNA damage response at telomeres mediated by ATR kinase and results in increased single-stranded telomeric DNA accumulation and decreased TERT binding to telomeres, leading to enhanced telomere shortening[26]. These findings establish TPP1 as essential not only for telomerase recruitment but also for maintaining proper telomere structure and preventing inappropriate DNA damage response activation at chromosome ends[26]. The TPP1-POT1 complex within shelterin cooperatively increases telomerase repeat-addition processivity by providing additional DNA-binding interactions that reduce dissociation of the DNA product from telomerase during multiple rounds of repeat synthesis[10][24][26].

POT1 and the Shelterin Complex in Telomerase Regulation

POT1 (protection of telomeres 1), another shelterin component, binds single-stranded telomeric DNA with high affinity and contributes to regulating telomerase access to telomeric overhangs through interactions with both telomeric DNA and TERT's TEN domain.[26][29] The POT1-DNA binding sequesters the telomeric overhang and assists in telomere capping, while also downregulating telomere elongation and ATR-dependent DNA damage response[26][29]. POT1 displays two N-terminal OB-fold domains involved in telomeric DNA binding, with high specificity for TTAGGG repeats[26][29]. The C-terminal portion of POT1 binds TPP1, allowing POT1 to link the single-stranded binding function at the chromosome end to the TPP1-mediated telomerase recruitment mechanisms[26][29].

Structural analysis of the POT1-TPP1 complex reveals multiple contact points between the C-terminal OB-fold of POT1 and the PBD (POT1 binding domain) of TPP1, with specific amino acid residues critical for this interaction identified[29]. Certain POT1 mutations that disrupt POT1-TPP1 binding can paradoxically lead to persistent telomerase access and longer, fragile telomeres, highlighting the protective role of the POT1-TPP1 complex in regulating telomerase activity at telomeres[29]. The fine-tuning of TERT recruitment and telomerase activity by the POT1-TPP1 complex demonstrates how the shelterin complex integrates multiple telomere-protective and telomere-regulating functions.

TRF1 and TRF2 as Negative Regulators of Telomerase

TRF1 and TRF2, which bind the double-stranded portion of telomeric DNA, function as negative regulators of telomerase activity at telomeres, with increased expression of these proteins leading to excessive telomere shortening and reduced telomerase-mediated elongation.[23][26] TRF1 suppresses telomerase action on telomeres, and overproduction of TRF1 excessively shortens telomeres[23]. TRF2 similarly negatively regulates telomere lengthening and acts as an inhibitor for telomerase enzyme activity[23][26]. These observations suggest that the balance between positive regulators like TPP1-POT1 and negative regulators like TRF1-TRF2 determines the net telomerase activity at telomeres and thus telomere length homeostasis[26].

Non-Canonical Functions of TERT

Mitochondrial Localization and mtDNA Protection

Under physiological conditions, approximately 10-20% of TERT protein localizes to mitochondria in association with mitochondrial DNA and mitochondrial tRNA, where TERT protects mitochondrial DNA against oxidative damage and may contribute to mitochondrial complex assembly and electron transport chain function.[15][18] The TERT protein contains a mitochondrial targeting sequence at its N-terminus, in addition to its nuclear localization signals, allowing it to be imported into mitochondria[15][18]. Upon acute oxidative stress, TERT is exported from the nucleus to mitochondria in a GTPase Ran-dependent manner, suggesting that one of the primary cellular responses to oxidative stress involves protection of mitochondria by translocating TERT to this organelle[15][18].

Mitochondrial TERT protects mtDNA against acute or UV-induced damage and decreases superoxide production and cellular reactive oxygen species (ROS) levels in primary human endothelial cells and cardiac tissue[15][18]. In cardiac mitochondria, TERT deficiency reduces state 3 respiration and impairs complex I function, consistent with a protective role for TERT in maintaining proper respiratory chain assembly and stoichiometry[15][18]. The mechanism by which mitochondrial TERT provides protection appears to involve binding and stabilization of mtDNA, possibly through interactions between TERT's reverse transcriptase domain and mtDNA or associated RNAs[15][18].

However, the exact mechanism by which TERT protects mtDNA remains incompletely understood, and conflicting results from different experimental systems have generated controversy regarding whether TERT directly protects mtDNA or indirectly does so through effects on respiratory chain assembly[15][18]. It is possible that TERT under certain circumstances increased respiratory chain activity through complex I, improving the balance between electron transport chain subunits encoded in nuclear and mitochondrial DNA, thereby reducing ROS production from imbalanced complexes[18]. The observation that sustained oxidative stress leads to reduction in mitochondrial TERT levels through Src kinase-mediated signaling suggests that mitochondrial TERT levels are dynamically regulated in response to cellular stress[15].

Regulation of Oxidative Stress and Anti-Apoptotic Functions

TERT overexpression in both tumor cell lines and primary non-transformed cells reduces basal cellular ROS levels and intracellular ROS generation in response to various stimuli while simultaneously inhibiting apoptosis, effects linked to increased reduced glutathione (GSH) and increased levels of nonoxidized peroxiredoxin.[15] TERT exerts anti-oxidative properties in non-transformed endothelial cells through a complex formation between TERT, the protein kinase Akt, and Hsp90, with this complex-mediated protection against apoptosis[15]. The mutual connection between TERT and ROS is evident from the observation that increased ROS levels lead to loss of TERT protein, an effect that can be prevented by antioxidant treatment[15].

In embryonic kidney cells and embryonic stem cells, TERT knockdown leads to increased intracellular ROS and enhanced susceptibility to oxidative stress, while conversely TERT overexpression reduces ROS and enhances stress resistance[15][18]. Differentiated cells derived from TERT-overexpressing embryonic stem cells show reduced intracellular ROS levels, suggesting that TERT effects on oxidative stress extend beyond acute stress conditions to influence the basal metabolic state and redox homeostasis of differentiated cell types[15]. These non-canonical functions of TERT in redox homeostasis highlight the enzyme's importance beyond its canonical telomere-lengthening role and suggest that in tissues with low telomerase activity, residual TERT expression may be maintained specifically for its antioxidant functions.

TERT in Gene Regulation and Signal Transduction

TERT has been implicated in regulation of gene expression through mechanisms independent of telomere lengthening, including modulation of c-MYC protein stability and interaction with transcriptional regulatory factors at specific gene promoters.[15][18] In the context of tumor biology, TERT has been shown to stabilize MYC protein levels and regulate MYC binding to target promoters, contributing to either activation or repression of MYC-target genes in a telomere-independent manner[18]. Additionally, TERT regulates expression of DNA methyltransferase 3B (DNMT3B), a de novo DNA methyltransferase, through mechanisms that remain to be fully elucidated[18]. TERT-mediated upregulation of DNMT3B expression leads to aberrant methylation of tumor suppressor genes including PTEN, resulting in silencing of PTEN and consequent enhancement of PI3K/AKT signaling that promotes cell survival and proliferation[18].

The discovery of TERT interactions with chromatin remodeling proteins and transcriptional regulatory factors suggests that TERT may function as a component of diverse cellular complexes involved in signal transduction and gene regulation beyond its role as the catalytic subunit of telomerase[18][20]. In multiple tumor cell lines, TERT physically associates with BRG1, a SWI/SNF-related chromatin remodeling protein, and nucleostemin, a nucleolar GTPase, forming a TERT-BRG1-nucleostemin complex that drives tumor-initiating cell formation by regulating BRG1 activity[10][39]. These findings indicate that TERT may be active at multiple subcellular locations and in diverse molecular contexts beyond the telomere, exerting effects on cellular differentiation, stemness, and transformation programs.

TERT in Human Disease and Aging

Dyskeratosis Congenita and Telomerase Deficiency Syndromes

Heterozygous and homozygous mutations in TERT cause dyskeratosis congenita and related telomere maintenance disorders, inherited bone marrow failure syndromes characterized by premature aging, short telomeres, and markedly elevated cancer risk.[1][56][59] The TERT protein is limiting for telomerase activity in differentiated cells, and mutations that reduce TERT function impair telomerase-mediated telomere maintenance, leading to accelerated telomere attrition despite continued cell division[56]. Patients with TERT mutations typically present with very short telomeres, low telomerase activity, progressive bone marrow failure, and increased susceptibility to malignancy, with the severity of disease correlating with the degree of telomerase impairment caused by the specific TERT mutation[56][59].

Notably, TERT mutations represent one of multiple genetic causes of dyskeratosis congenita, with heterozygous missense mutations in TERT causing autosomal dominant disease or disease-like features, while homozygous mutations cause more severe autosomal recessive dyskeratosis congenita[56][59]. The molecular mechanisms by which TERT mutations impair telomerase function vary, including mutations that abolish catalytic activity, disrupt RNA binding, impair protein folding, or alter nuclear localization[56][59]. The clinical phenotypes associated with TERT mutations demonstrate the critical importance of telomerase for maintenance of replicative homeostasis in tissues with high cell turnover such as bone marrow and skin epithelium[56][59].

Telomere Shortening and Cellular Senescence

Progressive telomere shortening represents a fundamental consequence of incomplete DNA replication during each cell division, with the end-replication problem causing approximately 50-100 base pairs of telomeric sequence loss per cell division in fibroblasts, ultimately triggering replicative senescence when telomeres reach critically short lengths.[25][28] Normal somatic cells lack telomerase expression and thus experience progressive telomere shortening with each replication, eventually reaching a critical length at which telomeres become dysfunctional and trigger a terminal cell cycle arrest termed the Hayflick limit[25][37][40]. The Hayflick limit, typically reached after 40-60 population doublings in human fibroblasts, represents a fundamental tumor-suppressive mechanism preventing unlimited cell division and malignant transformation[37][40].

Telomere shortening occurs through multiple mechanisms including the inherent incomplete replication of lagging strand synthesis, exonuclease degradation of single-stranded 3′ overhangs, and replication fork stalling at telomeric repeats prone to secondary structure formation[25][28]. The progression of replication fork through telomeres is hampered by telomeric sequences prone to forming secondary structures such as G-quadruplexes, tightly DNA-bound shelterin proteins, and the heterochromatic nature of telomeres[28]. When replication forks stall at telomeres and cannot be restarted, they collapse into double-strand breaks that must be appropriately repaired to prevent genomic instability[28]. Without active telomerase, normal telomere attrition during DNA replication acts as a tumor-suppressive barrier to unlimited cell divisions, with the achievement of critically short telomeres triggering DNA damage response activation and replicative senescence[28].

TERT Reactivation in Cancer and Immortalization

Over 90% of human cancers reactivate telomerase expression through TERT transcriptional activation, TERT promoter mutations, or alternative telomere lengthening mechanisms, thereby circumventing the replicative senescence barrier and enabling unlimited cell division.[16][38][41] The reactivation of telomerase occurs as a critical step in cancer development, allowing cells that have undergone extended proliferation and experienced telomere shortening to escape from replicative senescence and acquire unlimited replicative potential[16][38][41]. TERT promoter mutations represent one of the most frequently mutated regions in human cancer, particularly in melanomas and glioblastomas, and function as gain-of-function driver mutations that promote cancer immortalization[16][38][41].

Experimental evidence demonstrates that TERT promoter mutations alone are sufficient to promote immortalization and tumorigenesis in cell culture and in vivo mouse xenograft models[41]. Cells containing cancer-associated TERT promoter mutations while still maintaining normal differentiation capacity and genomic stability show increased TERT expression, elevated telomerase activity, and enhanced telomere length compared to wild-type controls[41]. Upon injection into mice, these TERT promoter mutant cells form tumors, establishing a direct causal relationship between TERT derepression and cancer development[41]. The prevalence of TERT promoter mutations in cancers with historically low telomerase expression levels supports a model wherein these mutations are specifically selected during cancer evolution in cells requiring telomerase reactivation to overcome proliferative barriers[38][41].

Conclusion: Synthesis of TERT Structure, Function, and Regulation

Telomerase reverse transcriptase represents a highly specialized enzyme with multifaceted regulatory mechanisms reflecting both its critical importance in telomere maintenance and its role in additional cellular processes. The structural organization of TERT into distinct functional domains—the TEN domain for DNA binding and protein interactions, the TRBD for RNA binding, the RT catalytic domain, and the CTE—reflects evolutionary specialization for template-directed repeat synthesis and processivity. TERT's catalytic mechanism, involving a two-metal-ion mechanism and three invariant aspartic acids, follows the general reverse transcriptase mechanism while incorporating telomerase-specific modifications that enable use of an internal RNA template and synthesis of multiple repeats without dissociation.

The regulation of TERT occurs at multiple levels, from transcriptional control involving the MYC/MAX/MAD network, Sp1, ETS factors, and epigenetic modifications of the TERT promoter, to post-translational modification through phosphorylation, ubiquitination, and protein-protein interactions with chaperones and regulatory factors. The discovery of cancer-associated TERT promoter mutations that create novel transcription factor binding sites represents a paradigm shift in understanding telomerase reactivation in cancer, establishing specific mutations as driver events rather than merely consequences of transformation. Nuclear import of TERT through a bipartite NLS and its regulation by phosphorylation-dependent mechanisms, 14-3-3 proteins, and SIRT1 establish TERT subcellular localization as a regulated parameter influencing telomerase activity.

The interaction of TERT with the shelterin complex, particularly TPP1-mediated recruitment to telomeres, represents the critical interface between telomerase and its substrate at chromosomes. The cooperative increase in repeat-addition processivity through TPP1-POT1 interactions demonstrates how accessory proteins enhance TERT's catalytic efficiency at physiological telomere lengths. The discovery of non-canonical TERT functions, including mitochondrial localization, ROS protection, and gene regulation, reveals that TERT operates in multiple cellular compartments and contexts beyond telomere elongation, suggesting that residual TERT expression in telomerase-negative tissues may be maintained for these alternative functions.

The importance of TERT in human biology is underscored by the association between TERT mutations and inherited telomerase deficiency syndromes like dyskeratosis congenita, the prevalence of TERT reactivation in cancer, and the inverse correlation between telomere length and TERT expression in determining cellular replicative capacity. Future research directions include better understanding of TERT's structural dynamics during the catalytic cycle, the mechanisms underlying TERT-mediated non-canonical functions, the therapeutic potential of selectively inhibiting TERT in cancer while sparing normal cells, and the role of TERT in age-related diseases. TERT exemplifies how detailed molecular understanding of enzyme structure, regulation, and function can illuminate both fundamental cellular processes and disease mechanisms relevant to human health.

Citations

1. https://en.wikipedia.org/wiki/Telomerase_reverse_transcriptase
2. https://www.pnas.org/doi/10.1073/pnas.94.17.9202
3. https://pubmed.ncbi.nlm.nih.gov/38749190
4. https://www.ncbi.nlm.nih.gov/gene/7015
5. https://pubmed.ncbi.nlm.nih.gov/9887342/
6. https://www.proteinatlas.org/ENSG00000164362-TERT
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC2943602/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5812681/
9. https://www.embopress.org/doi/10.1093/emboj/19.11.2652
10. https://www.nature.com/articles/s41419-024-06454-7
11. https://pubmed.ncbi.nlm.nih.gov/18522991/
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC165952/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2917597/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7267725/
15. https://www.nature.com/articles/s41388-019-0872-9
16. https://www.pnas.org/doi/10.1073/pnas.1402531111
17. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2019.00332/full
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC8096264/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC9736166/
20. https://pmc.ncbi.nlm.nih.gov/articles/PMC10813121/
21. https://www.science.org/doi/10.1126/science.aab4070
22. https://www.nature.com/articles/s41598-021-95239-5
23. https://pubmed.ncbi.nlm.nih.gov/1613801/
24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7276337/
25. https://www.nature.com/articles/s41420-025-02491-z
26. https://pmc.ncbi.nlm.nih.gov/articles/PMC8047117/
27. https://www.nature.com/articles/ncomms14928
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC10152985/
29. https://pubs.acs.org/doi/10.1021/acs.chemrev.4c00505
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC114356/
31. https://pmc.ncbi.nlm.nih.gov/articles/PMC280623/
32. https://pmc.ncbi.nlm.nih.gov/articles/PMC262686/
33. https://journals.asm.org/doi/pdf/10.1128/jvi.75.14.6337-6347.2001
34. https://www.embopress.org/doi/10.1093/emboj/19.16.4412
35. https://en.wikipedia.org/wiki/Hayflick_limit
36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4853035/
37. https://pmc.ncbi.nlm.nih.gov/articles/PMC3135819/
38. https://elifesciences.org/articles/07918
39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4470279/
40. https://www.uniprot.org/uniprotkb/O14746/entry
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC360416/
42. https://journals.biologists.com/jcs/article/125/11/2684/32311/Nuclear-import-of-hTERT-requires-a-bipartite
43. https://www.uniprot.org/uniprotkb/O14746/genomic-coordinates
44. https://www.pnas.org/doi/10.1073/pnas.1200232109
45. https://pubmed.ncbi.nlm.nih.gov/11847229/
46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4571862/
47. https://pmc.ncbi.nlm.nih.gov/articles/PMC3252576/
48. https://www.tandfonline.com/doi/abs/10.4161/cc.8.9.8288
49. https://academic.oup.com/nar/article/49/8/4768/6226674
50. https://www.nature.com/articles/ncomms5146
51. https://pmc.ncbi.nlm.nih.gov/articles/PMC10003760/
52. https://www.pnas.org/doi/10.1073/pnas.0800042105
53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5266692/
54. https://pmc.ncbi.nlm.nih.gov/articles/PMC2615648/